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ABSTRACT 
The opioid epidemic has drawn increasing attention as opioid prescribing rates and opioid 
related deaths continue to rise. Opioid prescribing by health care providers has quadrupled over 
the past 18 years and is directly proportionate to opioid-related overdoses. Primary care 
providers initiate chronic opioid pain management and frequently fail due to the multifaceted 
nature of chronic pain.  
A rural North Dakota health care system implemented strategies to improve chronic 
opioid pain management. Strategies were based on the 2016 Centers for Disease Control and 
Prevention Guideline for Prescribing Opioids for Chronic Pain. Interventions were directed at 
improving opioid prescribing practices for chronic non-cancer pain management of primary care 
providers and reducing risks of long term opioid use. Providing clinicians with education and a 
quick-reference sheet on current evidence-based recommendations and accepted best practices 
developed their knowledge to complete remaining interventions. Chart audits identified patients 
on chronic opioid therapy, patients with a signed pain contract, and those with daily opioid doses 
meeting or exceeding recommended upper daily morphine milligram equivalence. Provider 
notification of identified patients allowed for further recommended interventions. Chart flagging 
allowed providers to easily identify patients currently on a pain contract, patients eligible for a 
pain contract, and patients receiving the upper daily morphine milligram equivalence limits. 
Evaluation was performed four months after initiation of the project. Results showed the 
education provided increased clinicians’ knowledge and comfort in the evidence-based 
guidelines for managing chronic pain with opioids. Recommended monitoring strategies were 
improved after providers received education. Evaluation found the prescription drug monitoring 
program review and documentation had improved from 0 to 18. Annual urine drug screens 
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increased from 9 to 15. Eighty-five percent of pain contract eligible patients were enrolled in a 
pain contract. Evaluation of patients prescribed daily morphine milligram equivalence ≥ 50 and ≥ 
90 that had appropriate recommended interventions were 57% and 50% respectively. Forty-five 
pain management patients were identified at the time of evaluation and flagged in the electronic 
health record. Overall, each intervention implemented showed improvement upon comparison of 
pre-implementation and post-implementation data.  
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CHAPTER ONE. INTRODUCTION 
Background and Significance 
Multiple chronic non-cancer pain management guidelines exist for use in practice. These 
guidelines hold similar elements but variations of specific recommendations between guidelines 
cause confusion and inconsistencies in care (U.S. Department of Health and Human Services 
[USDHHS], 2016). The U.S. Department of Health and Human Services (2016) discussed many 
current guidelines and their formulation was built off evidence from studies prior to 2010. 
Clarity is needed between these variations of recommendations to provide clinicians with up-to-
date evidence for practice. Clinicians often fail to use guidelines and practices intended to 
decrease misuse and abuse risks (USDHHS, 2016).  
Chronic pain is a growing issue in the United States. The number of individuals affected 
by chronic pain are increasing each year (Hooten et al., 2013). Opioid pain medication 
prescribing habits of providers are directly proportionate with deaths related to prescription 
opioids (Centers for Disease Control and Prevention [CDC], 2014; USDHHS, 2016). In 2015, 
prescription opioids account for nearly half of United States opioid related deaths (USDHHS, 
2016). More than 15,000 overdose deaths involving prescription opioids occurred in 2015, 
averaging about 46 people each day. Since 1999, prescription opioid related overdose deaths and 
opioid prescribing habits of providers have quadrupled (CDC, 2016).  
Chronic Pain 
 Chronic pain can be defined multiple ways with varying durations of pain, intensity level, 
or activity interference (Currow, Phillips, & Clark, 2016). Chronic pain has multiple definitions 
throughout literature, including: pain lasting greater than three months, pain lasting greater than 
six months, and pain lasting longer than the normal amount of time expected for an injury 
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(Denenberg & Curtiss, 2016; USDHHS, 2016; Hooten et al., 2013). The Association for the 
Study of Pain defines pain as an emotional and unpleasant sensory experience associated with 
tissue damage (Rosenberg, 2013). The most prevalent definition is pain lasting longer than the 
expected time of healing for an injury or pain lasting greater than or equal to three months 
(Noble et al., 2016). Chronic pain results from underlying medical conditions, medical 
treatments, injury, inflammation, and unknown causes (Institute of Medicine, 2011). Many types 
of pain can be identified through research: nociceptive, neuropathic, psychogenic, idiopathic, 
inflammatory, muscle, and mechanical/compressive (Hooten et al., 2013; Rosenberg, 2013). 
Pinpointing pain is difficult because it is multi-faceted and ever-changing.  
Chronic pain has become an increasing issue in the United States that has created a 
burden of opioid overuse and abuse. More than 50 million adults are affected by chronic pain 
each year (Hooten et al., 2013). The National Health Interview Survey provided by the CDC 
reported 11.2% of United States adults had experienced chronic pain daily, three months prior to 
taking the survey (Nahin, 2015). Opioid pain medication has been a staple in treatment for acute 
and chronic pain. Acute pain increases the risk of developing chronic pain (IOM, 2011). 
Treatment using opioids for acute pain often leads to long-term opioid use. Early exposure and 
higher doses of opioid use for acute pain increases the risk of long-term opioid use (Alam et al., 
2012; USDHHS, 2016). Two different studies examine opioid use for acute pain leading to long-
term use. The first study identified that opioid use within seven days of low-risk surgery was 
associated with increased likelihood of opioid use at one year with an adjusted odds ratio of 1.44. 
The second study found that opioid use in the first 15 days after the onset of low back pain had 
an increased risk of long-term opioid use with an adjusted odds ratio of 2.08 (USDHHS, 2016).   
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Prevalence 
The prevalence of opioid prescriptions is astounding. The United States has an opioid 
consumption rate greater than any other nation. In 2012, 259 million opioid pain medication 
prescriptions were provided by health care clinicians, which is enough for every United States 
adult to have one bottle of opioids (CDC, 2014). From 2007 to 2012 per capita rates of opioid 
prescriptions increased by 7.3%. Growing popularity of prescribing opioid pain medication is 
seen among internal medicine, general, and family practice clinicians (Levy, Paulozzi, Mack, & 
Jones, 2015).  Growing rates of opioid prescriptions is disproportionate to the health status of the 
United States population (CDC, 2014; USDHHS, 2016). According to the USDHHS (2016) 
“9.6-11.5 million adults, or approximately 3%-4% of the United States adult population, were 
prescribed long-term opioid therapy in 2005” (p. 2). A National Survey on Drug Use and Health 
performed by the USDHHS reported that in 2010, roughly 1 in every 20 individuals, 12 years 
and older, used opioids recreationally (Del Portal, Healy, Satz, & McNamara, 2016). While 
chronic opioid therapy possesses legitimate therapeutic uses, prescribers should consider the 
negative consequences that may result from chronic opioid therapy.  
Negative Consequences of Opioid Prescribing   
 Increasing opioid prescriptions are directly proportional to abuse and overdose rates. 
Clinicians deem opioid abuse as a major public health issue (Del Portal, Healy, Satz, & 
McNamera, 2016). Opioid pain medication related deaths amounted to more than 165,000 people 
from 1999 to 2014 in the United States. Of these deaths, rates were highest in ages 25 to 54 
years, men, non-Hispanic whites, American Indian, and Alaskan Natives as compared to non-
Hispanic blacks and Hispanics (USDHHS, 2016). Prescriptions are fueling the opioid epidemic 
in the United States, as half of opioid related overdose deaths are a result of prescription opioids. 
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Over 14,000 United States deaths in 2014 were a result of prescription opioid medication 
(USDHHS, 2016). 
Opioid use disorders are another area of concern with increasing rates of prescription 
opioids. In 2011, estimates of greater than 420,000 visits to the emergency room were a result of 
opioid pain medication misuse or abuse (USDHHS, 2013). Hahn (2011) compared non-opioid 
abusers to opioid abusers and found that opioid abusers have higher rates of provider and 
emergency room visits, hospital admissions, motor vehicle accidents, documented trauma cases, 
and abuse treatment. Drug abuse is the habitual or continued ingestion of addictive or illegal 
drugs (Martin, Zieve, & Ogilvie, 2016). Drug misuse is defined by the National Institute on Drug 
Abuse (2016) as “taking a medication in a manner or dose other than prescribed; taking someone 
else’s prescription, even if for a legitimate medical complaint such as pain; taking a medication 
to feel euphoria; or nonmedical use of prescription drugs” (p. 1). 
Opioid use disorders are often demonstrated by the following characteristics: 
unsuccessful efforts to cut down, unsuccessful efforts to control use, and failure to uphold 
routines of life at home, work, or school (American Psychiatric Association [APA], 2013). 
Although opioid abuse is growing, the phenomenon should not be confused with those who have 
a tolerance and physical dependence to the medication. Behavior differences exist between 
tolerance and physical dependence. Tolerance describes reduced efficiency of medication effects, 
such as pain relief, after recurrent use (USDHHS, 2014). Physical dependence describes the 
body’s physical reliance on a medication that produces withdrawal symptoms when the 
medication is stopped abruptly (USDHHS, 2014). Opioid pain medication is over-prescribed for 
individuals with all types of pain. Over-prescribed can be defined as prescribing opioids for 
prolonged periods of time when not indicated, opioids being prescribed as a first-line treatment 
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when other non-pharmacological and non-opioid pharmacological treatments have been tried, or 
opioids are continually prescribed in larger doses when no therapeutic effect is achieved 
(USDHHS, 2016). Addiction is commonly a consequence of over-prescribing and prolonged 
opioid use (Wilson et. al, 2013). Evidence supports that increased opioid dosage is related to the 
risk of addiction and overdose associated with chronic opioid therapy (USDHHS, 2016). Further 
exploration into interventions reducing opioid overprescribing, opioid abuse, and overdose is 
needed.   
Cost 
Chronic pain treatment in the United States has amounted to more than half a trillion 
dollars every year. Pain is one main reason people seek out a primary care provider (American 
Academy of Pain Medicine [AAPM], 2013). Healthcare costs of opioid abusers were eight times 
higher than non-opioid abusers (Hahn, 2011). Further breakdown showed, on average, an 
individual who abuses opioids incurs increased health care costs of $15, 884 per year. In 
comparison, non-abusers spend an average of $1,830 per year (Hahn, 2011). According to Hahn 
(2011), “prescription costs were five times greater for abusers compared with non-abusers with a 
mean cost of $2,034 vs $386 respectively” (p. 109). An estimated $174 billion is spent annually 
on pain management by society and the health care system. The estimated cost of chronic pain 
on lost productivity in the workforce amounts to 61.2 billion per year (Rosenberg, 2013). 
Improving pain management, functionality, and quality of life, while decreasing rates of opioid 
prescriptions, opioid misuse, and overdose would significantly affect the current cost of chronic 
pain management.  
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Impact 
 Chronic pain affects many aspects of life for individuals living with it including but not 
limited to: neurological system, emotions, behavior, ability to perform daily tasks, ability to 
work, social responsibilities, and quality of life (Agency Medical Directors’ Group [AMGD], 
2015; USDHHS, 2013; IOM, 2011). Chronic non-cancer pain has been found to be the leading 
cause of long-term disability. Americans affected by pain totals more than those with conditions 
such as diabetes, heart disease, and cancer combined (USDHHS, 2013). Increasing pressure to 
improve pain, management and reduce prescription opioids use occur along a continuum, making 
it difficult for providers to achieve balance. Patient expectations shape health care encounters. 
Patients seeking care expect clinicians to provide an intervention that the patient could not 
achieve at home, therefore, they may become dissatisfied when clinicians fail to meet those 
expectations. An example would be, a patient seeking care for pain and expecting to receive a 
prescription pain medication but instead receives a referral to physical therapy or education on at 
home care of pain including over the counter pain medications (Zgierska, Miller, & Rabago, 
2012). Dissatisfied patients may rate the entire visit experience on whether or not they received a 
prescription in comparison to the overall visit experience. Due to increased focus on patient 
satisfaction scores providers feel pressured to achieve positive patient experiences. Quality of 
care and patient satisfaction target scores have become a driving force behind clinician 
compensation. Facilities set benchmarks on satisfaction scores and may use these scores in 
consideration when reviewing the provider’s salary, job retention, or job promotions. Increased 
availability of circulating opioids, prescription opioid diversion, misuse, and related harms are 
direct consequences of the patient satisfaction scores driving quality of care, facility 
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reimbursement, and provider compensation (Zgierska, Miller, & Rabago, 2012). Chronic pain is 
a serious issue that needs attention and intervention (Currow et al., 2016). 
Purpose 
The quality improvement project provided clinicians with tools and processes using 
evidence-based guideline recommendations and accepted best practices offering solutions to 
problematic prescribing, encouraging positive change in prescribing habits, expanding provider 
knowledge, optimizing patient care, and improving patient safety by reducing risk of long term 
opioid use. The practice improvement interventions targeted primary care providers who care for 
chronic pain patients. Patients 18 years and older on chronic pain therapy in a rural health care 
setting were the population of focus. The project pushes for practice change leading to decreased 
circulating opioids that are being misused and contributing to the epidemic of opioid overdose 
(USDHHS, 2016).   
Congruence of the Project to the Organization’s Goals  
 In discussing the needs of Coal Country Community Health Clinic with Dr. Aaron 
Garman, medical director, opioid overprescribing, lack of confidence in opioid prescribing, and 
lack of education on opioid prescribing were identified as the primary needs. Working in 
conjunction with the organization, a plan was designed to fit best within the constraints of the 
project, but also providing benefit to the clinic. The overall goal of the project is to improve 
prescribing practices among providers in rural health settings.  
Objectives  
1.   Provide education regarding current chronic pain management recommendations and 
accepted best practices from the 2016 CDC guidelines for: 
a.   Prescription Drug Monitoring Program (PDMP) use 
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b.   Urine drug screens (UDS) 
c.   Morphine Milligram Equivalence (MME) dosing 
d.   Pain contracts  
2.   Flag all patients on a pain contract within the EHR using a uniform system.  
3.   Identify all patients without a pain contract who have been prescribed opioids ≥ 3 months 
and enroll identified patients in a pain contract over a 4-month period.  
4.   Determine all patients who have been prescribed opioids ≥ 3 months and who are 
receiving doses that place them at increased risk (patients prescribed doses ≥ 50 MME 
per day and prescribed ≥ 90 MME per day). Develop strategies to reduce risk associated 
with upper daily limits of opioids.  
5.   Develop sustainability practices to ensure compliance and continued monitoring of 
implemented recommendations for chronic pain management patients upon completion 
of project. 
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CHAPTER TWO. LITERATURE REVIEW AND THEORETICAL FRAMEWORK 
Review of Literature 
A literature review was conducted using evidence-based articles found in the following 
databases: EBSCOhost, PubMed, CINAHL, and Cochrane. Keywords included opioids, pain, 
chronic pain, pain management, contract, pain contract, prescribing, practices, prescribing 
practices, prescription, adherence, therapy, opioid therapy, drug, attitudes, pharmacy, risk, 
assessment, aberrant, behavior, primary, care, narcotics, monitoring, substance, abuse, health 
care, guidelines, analgesics, monitoring, diversion, and controlled substances. All searches were 
focused on finding articles pertaining to chronic opioid therapy for pain management. The 
literature review identified the CDC Guideline for Prescribing Opioids for Chronic Pain, released 
by the CDC in March of 2016, as the most current set of chronic pain management guideline 
with strong supporting evidence. The CDC guideline will be used as a footprint for this project.  
Introduction 
Opioid abuse and misuse continues to be a growing topic of interest. Over the past 
decade, the number of opioid prescriptions has increased. The strongest counterweight for opioid 
over-prescribing is awareness and education, and those elements are where recent efforts to curb 
opioid over-prescribing have been focused. Opioids are effective tools to relieve acute and 
chronic pain, but for clinicians, abuse and misuse of opioids creates strain on chronic pain 
management (USDHHS, 2016). Treating chronic pain with opioid medication poses a challenge 
for clinicians. Research and recent evidence provides a foundation to improve management of 
pain with opioids and opioid prescribing habits of clinicians through guidelines. Current 
guidelines focus on reducing the negative consequences of rise in opioid prescriptions while 
improving patient quality of life. Currently, many organizations rely on pain management 
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guidelines aimed at universal use for all clinicians leading to uniformed prescribing and 
improving quality care for all chronic pain management patients. In the early months of 2016 the 
CDC released a universal chronic pain management guideline based off the latest evidence 
(USDHHS, 2016).  
Pain Management Guidelines 
One suggested way to reduce overprescribing, opioid abuse, and addiction is to provide 
guidelines and streamline chronic non-cancer pain management (USDHHS, 2016). Clinicians 
have shown concern with patient misuse and addiction to opioid pain medication. Additionally, 
clinicians report stress related to managing chronic pain, as well as inadequate education 
regarding prescribing opioids (Jamison, Sheehan, Scanlan, Matthews, & Ross, 2014). Building 
an opioid management protocol can decrease rates of opioid prescriptions and allow for close 
management of those taking long-term opioid pain medication (USDHHS, 2016). 
Opioid prescriptions, opioid abuse, and overdose rates continue to increase. The use of an 
opioid management guideline has been recommended by the American Pain Society, American 
Academy of Pain Medicine, Agency Medical Directors’ Group, the U.S. Department of Veterans 
Affairs, and the CDC. Recently the USDHHS suggested using pain management guidelines as a 
tool for clinical decision making among health care clinicians. The overall goal for chronic pain 
treatment guidelines is not achieving a pain free state but aims interventions at reducing the 
problem of improper prescribing habits and drug abuse while improving pain management, 
decreasing suffering, and improving function and quality of life (AAPM, 2013; Currow et al., 
2016; Denenberg & Curtiss, 2016; Rosenberg, 2013). A study done by Von Korff (2016) found 
that a set of guidelines in Washington state helped health care providers decrease both opioid 
dose amounts and excess opioid days supplied to patients.  
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Many different variations of opioid management guidelines exist. Evidence-based 
practice can be used to guide improving patient outcomes (USDHHS, 2016). One study found 
that when combined, referrals to specialist services, urine drug screening, pharmacy drug 
monitoring, treatment agreements, and patient education reduced substance misuse by 50% 
(Currow et al., 2016). Current research concluded with medium strength evidence that 
interventions such as patient assessment, risk-screening tools, controlled substance agreements, 
careful dose titration, opioid dose ceilings, and adherence to practice guidelines reduce the risk 
of inappropriate prescription drug-related behaviors (Currow et al., 2016; Denedberg & Curtiss, 
2016; USDHHS, 2016). Although medium strength evidence is found throughout research, 
experts have taken current evidence and made strong suggestions in building new guidelines to 
aid in chronic pain management (Currow et al., 2016; Denedberg & Curtiss, 2016; USDHHS, 
2016).  Standardizing guidelines to use in practice will provide structure, improve patient care, 
and provide evidence-based framework across practice (AAPM, 2013). The AAPM (2013) 
identified the importance of patient-centered care for diagnosing and treating pain that is 
comprehensive, systematic, and collaborative.  
Guidelines include an array of risk mitigation strategies: risk assessment instruments, 
opioid management plans, patient education, urine drug screening, use of prescription drug 
monitoring programs, pill counting, and pain management contracts. Risk mitigation is difficult 
to evaluate due to lack of supporting studies with sufficient evidence showing improvements in 
overdose, addiction, abuse, or misuse outcomes (USDHHS, 2016). One set of guidelines suggest 
a trial of opioid therapy prior to making a final decision to use opioids as a means of chronic pain 
management. The length of trial is based on clinical judgement, and enough time should be 
provided to make an informed decision regarding if the current prescribed opioid improves pain, 
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function, and quality of life (Chou et al., 2014). Current guidelines available combine multiple 
risk mitigation strategies. 
Pain Management 
  The approach for pain management should be a combination of therapies to reduce pain 
intensity, improving functionality and quality of life (Chou et al., 2014). Safer alternatives to 
opioid therapy exist which can be equally effective long-term. (AMDG, 2015). Current 
guidelines hold similar views that begin by assessing the current individual and building a 
comprehensive multi-therapy management combining nonpharmacological interventions and 
non-opioid medication as the first line treatment (Denenberg & Curtiss, 2016; USDHHS, 2016; 
Hooten et al., 2013). Major goals of long-term pain management in chronic non-cancer pain is a 
reduction in pain level, anxiety, and adverse effects while improving functional ability, quality of 
life, rates of individuals returning to work, and cost-effective care (National Guideline 
Clearinghouse [NGC], 2013). Complete pain relief is not expected with long-term opioid 
therapy. Clinicians should discuss realistic expectations of benefits from therapy (USDHHS, 
2016).   
Non-Opioid Therapy  
Chronic pain management can produce challenges in decreasing pain, improving 
function, and quality of life. Nonpharmacological and non-opioid pharmacologic therapies 
should be first line therapy for chronic pain. Non-opioid analgesics such as acetaminophen, 
nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants, and anticonvulsants have been 
found to be equally or more effective in treating chronic pain while inducing less risk and harm 
than opioids (AMDG, 2015; Denedberg & Curtiss, 2016). Initial treatment should be determined 
by the cause of pain (AMDG, 2015; Chou et al., 2014).   
 13 
Adjunctive non-pharmacological pain interventions have not been suggested for sole use 
but are to be used in combination with pharmacological interventions. Nonpharmacological 
interventions include relaxation, guided imagery, acupuncture, message, acupressure, 
aromatherapy, reflexology, yoga therapy, music therapy, use of distraction, heat and cold 
therapy, electrotherapy, cognitive behavioral therapy, spiritual therapy education, exercise, 
physical therapy, epidural injections, and steroid injections (AMDG, 2015; Denenberg & Curtiss, 
2016; Gregory, 2014; USDHHS, 2016; Hooten et al., 2013; NGC, 2013; Rosenberg, 2013). 
Alternative treatments such as cognitive behavioral therapy have been shown to modify 
cognitive processes and environmental factors decreasing pain perception (USDHHS, 2016).  
Exercise therapy has improved pain, function, and well-being in individuals with osteoarthritis of 
the knees and hips, chronic low back pain, and fibromyalgia (USDHHS, 2016; Hooten et al., 
2013). 
Non-opioid analgesics should be used as first line treatment for chronic management 
(USDHHS, 2016). Non-opioid treatment options for pain include NSAIDs, acetaminophen, and 
cyclooxygenase 2 (COX-2) inhibitors (Chou et al, 2014; USDHHS, 2016). These medications 
are not advised without risk. Nonsteroidal anti-inflammatories are associated with gastritis, 
peptic ulcer disease, cardiovascular events, fluid retention, and can interfere with platelet 
aggregation. Acetaminophen is associated with hepatotoxicity (Chou et al. 2014; USDHHS, 
2016).  
Other non-opioid medications that providers can contemplate are tricyclic antidepressants 
(TCAs), serotonin-norepinephrine reuptake inhibiters (SNRIs), and anticonvulsants (gabapentin, 
pregabalin) for neuropathic pain, centralized pain syndromes, and fibromyalgia. Lack of long-
term benefits from muscle relaxants means they should not be prescribed for more than a few 
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weeks (AMDG, 2015; Chou et al., 2014; Hooten et al., 2013).  Guidelines agree first and second 
line drug management for neuropathic pain are anticonvulsants and antidepressants (USDHHS, 
2016; Hooten et al., 2013). 
Existing treatment guidelines hold similar beliefs in the progression of chronic pain 
management starting preferably with a combination of non-pharmacological and non-opioid 
analgesic and build up to opioids if needed (Denenberg & Curtiss, 2016; USDHHS, 2016; NGC, 
2013). Once opioid therapy is initiated, risk mitigation strategies should be considered. 
Combining therapies that are both physical and psychological have been found to be more 
effective in reducing pain and improving function in comparison to single therapies (USDHHS, 
2016; Lee, Crawford, & Swann, 2014).  
Naloxone and methadone are not used directly for pain management, but the two 
medications are important in providing care to patients with high risk of opioid overdose and 
have an opioid addiction.  Long-term opioid therapy carries concern of misuse and abuse. 
Incorporation of naloxone should be considered for individuals with risk factors for opioid 
related harms. Naloxone is an opioid antagonist that reverses the effects of opioids such as 
respiratory depression. The medication may be administered by family or friends to save the 
lives of individuals who have overdosed on opioids. For patients with physical dependence on 
opioids, naloxone can precipitate acute opioid withdrawal (USDHHS, 2016). Risk factors for 
opioid related harms include history of overdose, history of substance use disorder, higher 
dosages of greater than or equal to 50 MME/day, or concurrent benzodiazepine use (Currow et 
al., 2016; USDHHS, 2016). Concurrent with naloxone, use of mitigation strategies should be 
used (USDHHS, 2016). Positive outcomes by community-based prevention programs show 
decreased opioid overdose risk and opioid overdose deaths when prescribing naloxone in 
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combination with opioid therapy (Walley et al. 2013). Methadone is also recommended for when 
opioid therapy has failed (Manchikanti et al., 2012). Methadone should not be prescribed with 
chronic pain management by clinicians without proper knowledge about methadone’s 
pharmacokinetics, unpredictable clearance, multiple drug-to-drug interactions, and additional 
monitoring requirements (AMDG, 2015; Chou et al., 2009). Methadone related deaths account 
for one-third of all opioid-related overdose deaths and is increasing (USDHHS, 2016; CDC, 
2012; Ray et al., 2015). 
No matter the treatment, benefits must always outweigh the risks prior to initiation and 
throughout therapy. Strong evidence shows more benefits and less risks are involved with 
nonpharmacological and non-opioid pharmacologic treatments when compared to long-term 
opioid therapy (USDHHS, 2016).   
Opioids Therapy For Chronic Pain Management  
Opioid therapy for chronic pain management remains controversial. Weak evidence 
supports the use of opioids for long-term therapy of chronic non-cancer pain. Poor evidence 
exists showing improvement of pain and function with use of opioids (USDHHS, 2016; Chou et 
al., 2014). Failure of opioid pain therapy to initiate early pain relief, within one month, is 
associated with lower success of pain relief with long-term opioid therapy (USDHHS, 2016). 
Opioids should be used as a last resort treatment method and should only be prescribed when 
other treatment modalities have failed (AAPM, 2013: AMDG, 2015; NGC, 213). The 
International Association for the Study of Pain identifies opioid prescriptions lasting longer than 
90 days within the past 120 days constitutes chronic opioid therapy (Currow et al., 2016). Full 
pain relief is often difficult to achieve in individuals with chronic pain, therefore obtainable pain 
level goals should be discussed (USDHHS, 2016; Chou et al., 2014).  
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Many different opioids exist and vary in indication and strength. Treating mild to 
moderate pain when non-opioid treatment modalities have failed would indicate weak opioids 
including codeine and tramadol. Moderate to severe pain would indicate strong opioids such as 
hydrocodone, morphine, oxycodone, fentanyl, and hydromorphone (Gregory, 2014). Treatment 
regimens the patient has previously tried and the severity of their pain will help determine which 
opioid to prescribe.  
Upon initiation of opioid therapy clinicians should start with the lowest effective short 
acting dose possible, and one deemed medically necessary (AMDG, 2015; USDHHS, 2016; 
Manchikanti et al., 2012). Long-term opioid therapy manifests tolerance and loss of 
effectiveness. Continued use will be dependent on factors of improved pain, physical function, 
quality of life, reduced adverse effects, and behaviors of misuse and abuse (AAPM, 2013; NGC, 
2013). During therapy, if risks outweigh the benefits, optimization of other therapies and 
tapering to lower doses or discontinuing opioid therapy is appropriate (Chou et al., 2014; 
Denenberg & Curtiss, 2016; USDHHS, 2016). Opioid therapy for chronic pain management is 
absolutely contraindicated in individuals with respiratory instability, acute psychiatric instability, 
uncontrolled suicide risk, active or history of substance abuse, confirmed allergy to the drug, 
life-limiting drug interaction with another medication, or diversion (Manchikanti et al., 2012). 
Prescribing opioids for acute pain can cause lasting consequences. Long-term opioid 
therapy often results from acute pain management with opioids (Alam et al., 2012; USDHHS, 
2016). Strategies for clinicians to reduce risk of transition to long-term opioid use includes the 
following: prescribe the lowest dose possible, prescribe short acting narcotics whenever possible, 
and prescribe only the quantity needed for the expected timeframe of severe acute pain. Seven 
days of severe pain is rare, up to three days of opioid pain medicine will usually be sufficient to 
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treat severe acute pain (USDHHS, 2016). Acute pain needs to be managed appropriately to 
reduce risk of long-term opioid therapy.  
Benefits  
 Opioid use for chronic pain management is a topic of interest. Evidence supporting the 
benefits of using long-term opioids for chronic non-cancer pain is inadequate and weak (Currow 
et al., 2016; Noble, 2016; AMDG, 2015). Many current guidelines acknowledge little data 
supporting use of opioids for long-term or more than three months (Currow et al., 2016). 
Although, providers should not disregard the use of opioids in treating pain. An estimated 40%-
70% of patients on long-term opioid therapy for chronic pain do not achieve effective analgesia, 
leaving 30%-60% who do (Currow et al., 2016).  
Risks  
Opioid therapy for chronic pain management holds consequences. Many adverse effects 
are associated with opioid medications including misuse and abuse. Improper prescribing and 
pain management contributes to these effects. Providers should be cautious when prescribing 
opioids. Common side effects from opioids include: constipation, sedation, dry mouth, nausea, 
vomiting, respiratory depression, and dizziness. Most side effects diminish with time except 
respiratory depression and constipation which persist (AMDG, 2015; Chou et al., 2014; Currow 
et al., 2016; Denenberg & Curtiss, 2016; USDHHS, 2106). Side effects that are less common 
include: urinary retention, confusion, delirium, hallucinations, muscle rigidity, and hyperalgesia 
(AMDG, 2015; Chou et al., 2014; Currow et al., 2016; USDHHS, 2106). Gonadotrophin-
releasing hormone (GnRH) suppression occurs with opioid use at the hypothalamus. GnRH 
suppression causes complications such as: increased bone mineral density loss, decreased muscle 
mass, immunologic and hormonal dysfunction, hypogonadism, amenorrhea, oligomenorrhea, 
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decreased sexual drive, and erectile dysfunction (AMDG, 2015; Denenberg & Curtiss, 2016; 
USDHHS, 2106). Side effects should be treated appropriately when opioid management benefits 
continue to outweigh the risks (Chou et al., 2014). At the start of long-term opioid therapy, 
implementation of a bowel regimen needs consideration, including: prescribing regular laxatives, 
medication specific for opioid induced constipation (naloxogel, methylnaltrexone, and 
lubiproston), stool softeners, increasing hydration, increasing fiber intake, and increasing 
physical activity (AMDG, 2015; USDHHS, 2016; Manchikanti et al., 2012).  
Long-term opioids run the risk of tolerance, physical dependence, and withdrawal 
symptoms when stopped abruptly (AMDG, 2015; Chou et al., 2014; Denenberg & Curtiss, 
2016).  Opioid tolerance occurs at a slow rate and is used to describe the body’s ability to 
become tolerant of certain side effects such as sedation, nausea and vomiting, euphoria, and 
anxiety. Tolerance to analgesic effects causes current prescribed doses to become less effective 
over time and can be recognized through assessment (Denenberg & Curtiss, 2016). Physical 
dependence is the body’s ability to adapt to the opioid medication causing withdrawal symptoms 
when abruptly stopped, and is an expected effect of long-term opioid therapy, withdrawal 
symptoms occur about 12 hours after the last dose (Denenberg & Curtiss, 2016). Withdrawal 
symptoms are recognized as sympathetic arousal, elevated heart rate and blood pressure, 
pupillary dilation, goose bumps, anxiety, jittery behavior, nausea, diarrhea, runny nose, yawning, 
myalgia, and insomnia (Denenberg & Curtiss, 2016). Treatment for withdrawal symptoms 
include resuming opioids or use of an alpha-blocking agent such as clonidine. Opioid tapering 
will help reduce withdrawal symptoms (Denenberg & Curtiss, 2016).  
Concurrent use of opioids, neuro depressants, or sedating medications increase risk of 
sedation, hypoventilation, falls, accidents, unintentional death and sudden death and therefore 
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should be limited (AMDG, 2015; Currow et al., 2016; Denenberg & Curtiss, 2016). Neuro 
depressants and sedating medications include: alcohol, benzodiazepines, carisoprodol, zolpidem, 
butalbital, gabapentin, pregabalin, hydroxyzine, and promethazine. When combining use of 
opioids and benzodiazepines, risk for potential fatal overdose increases by 31-61% (Dasgupta et 
al., 2015; Gomes et al., 2011; USDHHS, 2016; Jones & McAninch, 2015).  
Risk of cardio-respiratory events increase when individuals on long-term opioid therapy 
have underlying sleep apnea and end-stage respiratory disease (AAPM, 2013; USDHHS, 2016). 
Risk of respiratory depression limits provider use of opioids in pain management (AAPM, 2013; 
AMDG, 2015). Risk of myocardial infarction when taking long-term opioids increases by 28% 
(Currow et al., 2016). Prescribing opioids to older patients doubles their risk of falls and 
fractures when taking greater than or equal to 50 MME daily (AMDG, 2015; Rolita, Spegman, 
Tang, & Cronstein, 2013). Increased risk of adverse effects increases in patients with hepatic and 
renal insufficiency. Impaired hepatic or renal function may result in metabolism changes causing 
increased half-life, amplified effects, and decreased amounts requiring respiratory depression and 
overdose. As individuals age, a natural decline of organ function begins, therefore, clinicians 
must pay special attention to individuals greater than or equal to 65 years because affects from 
changed metabolism occur at an increased rate (Currow et al., 2016; USDHHS, 2016). 
Pregnant women using opioids are at an increased risk for birth defects, neural tube 
defects, congenital heart defects, gastroschisis, poor fetal growth, and neonatal opioid 
withdrawal syndrome occurring after birth. Opioid use during pregnancy also increases risk for 
preterm delivery and still births (Broussard et al. 2011; Chou et al., 2014; USDHHS, 2016; 
Yazdy, Mitchell, Tinker, Parker, & Werler, 2013). Opioid use during pregnancy is 
contraindicated.  
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Increased risk for opioid use disorders has been linked with mental health disorders, 
history of substance use disorders, and history of nonfatal overdose (USDHHS, 2016; Howe & 
Sullivan, 2014). Some mental health disorders such as depression increases risk of opioid related 
overdoses and is directly proportionate to dose (Turner & Liang, 2015). Psychological issues 
arise from long-term opioid use as well, depression in those not previously depressed, induced 
anxiety, and lower self-efficacy (Currow et al., 2016; USDHHS, 2016). Overuse and abuse of 
opioid therapy has become an increasing issue across the United States. Risk of misuse, 
psychological dependency, and overdose increases in patients on long-term opioid for chronic 
non-cancer pain (Currow et al., 2016).  
Assessment 
Assessment holds to be one key element in all clinical practice guidelines and existing 
research. Assessment identifies an initial pain management treatment plan based off what has or 
has not been tried in the past, improvement in function and pain, and drives changes in the 
treatment plan (Manchikanti et al., 2012). Initial assessment prior to starting any treatment 
should include: past medical history, extensive pain history, impact of pain, physical 
examination, review of previous diagnostic studies, review of previous treatments, substance use 
history, psychological history, psychosocial history, and comorbidities. (AAPM, 2013; AMDG, 
2015; Chou et al., 2014; Denenberg & Curtiss, 2016; Hooten et al., 2013; Manchikanti et al., 
2012; Rosenberg, 2013). Additional diagnostic testing may be warranted if previous tests are 
outdated or missing (Rosenberg, 2013). 
Aside from the initial assessment, frequent reassessment aids in determining the response 
to pain management by assessing the functional status, pain intensity, continued analgesic effect, 
adverse effects, progress towards therapeutic goal achievement, quality of life, therapy 
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adherence, and medication misuse (AAPM, 2013; AMDG, 2015; Chou et al., 2014). Pain and 
functional assessment should demonstrate clinically meaningful improvement, which is defined 
as at least 30% improvement in pain and function compared to initial or last dosage of opioid 
therapy (AMDG, 2015; USDHHS, 2016). The Pain average, interface with Enjoyment of life, 
and interference with General activity (PEG) assessment scale is a validated tool to be used in 
evaluating pain and function outcomes over time (USDHHS, 2016).  Decreased pain with failure 
to improve function does not meet the clinically meaningful improvement standard (AMDG, 
2015). Long-term opioid therapy may be continued if accompanied by monitoring adherence, 
improved function abilities, and improved pain (Manchikanti et al., 2012). If current or increased 
opioid dosages fail to produce clinically meaningful improvement, opioid therapy should be 
tapered back or discontinued while optimizing non-opioid therapies (AMDG, 2015; Chou et al., 
2014; USDHHS, 2016; Hooten et al., 2013).  
Initial and continuous assessment plays a strong role in pain management. Risks and 
benefits should be examined with the individual prior to initiation and dose increase of pain 
therapy, while being revisited every three months or more as needed. Low risk individuals 
should be monitored every three to six months (Chou et al., 2014; USDHHS, 2016). Individuals 
with a history of substance use disorders, mentally demanding occupations, older adults, 
dysfunctional social environments, comorbid psychiatric or medical condition should be 
monitored more often than every three to six months. Weekly reassessment should be standard 
for high risk individuals (Chou et al., 2014; USDHHS, 2016). Strategies reducing risk should be 
incorporated into the plan of care (Chou et al., 2014; USDHHS, 2016). During reassessment 
pharmacy checks, urine drug screens, pill counts, and family interviews can provide useful 
 22 
information on adherence (Chou et al., 2014). Assessment and monitoring require constant 
attention.  
Assessment Tools  
Multiple tools are available to measure potential and current opioid abuse risk. Experts 
agree that validated instruments may assist in monitoring and tracking compliance, aberrant 
behavior, and patient outcomes (USDHHS, 2016; Hooten et al., 2013).  Among these tools that 
have been validated and used in existing guidelines include the Opioid Risk Tool (ORT), The 
Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R), and the Brief Risk 
Interview (BRI). Lack of sufficient evidence for all assessment tools make it difficult to decipher 
which one should be used (Chou et al., 2014). The ORT had a sensitivity of 75% and specificity 
of 86%, the SOAPP-R had a sensitivity of 25% and specificity of 73%, and the BRI had a 
sensitivity of 83% and specificity of 88% (Jones, Lookatch, Grant, McIntyre, & Moore, 2014; 
Jones & Moore, 2013). Experts recommend screening for opioid misuse and abuse even though 
limited evidence exists for accuracy and reliability of screening (Manchikanti et al., 2012). 
Dosing Restrictions  
Literature inconsistency on safe dosing of opioids makes prescribing difficult. Higher 
rates of opioid abuse and dependence are associated with increased doses of long-term opioid 
therapy in comparison to low doses (Edlund et al., 2014). One study found high opioid doses 
were associated with increased cases of worker’s disability compensation. A decrease in the 
number of deaths related to opioids was found when clinicians prescribed opioid doses less than 
120 MME per day (Von Koff, 2016).  Throughout literature, prescribers have been cautioned 
against using doses greater than 90 MME to 200 MME (Currow et al., 2016). Fair evidence 
identifies dosing categories for opioids: low dose as 40 MME or less per day, a medium dose as 
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41-90 MME per day, and high doses to be somewhere greater than 91 MME per day 
(Manchikanti et al., 2012).  Overall, overdose risk increases with higher opioid dosages 
(USDHHS, 2016).  Increasing opioid dosages requires evidence through reassessment indicating 
benefits outweigh the risks of doses ≥ 50 MME/day. Clinicians should restrain from prescribing 
doses ≥ 90 MME/day (USDHHS, 2016). Special consideration needs to be taken when dosing 
opioids for opioid-naïve individuals and the elderly population (Denenberg & Curtiss, 2016).  
Comparing extended-release or long-acting and immediate-release opioids has been a 
topic of controversy. Extended-release in comparison to immediate-release opioids are 
associated with increased risk of non-fatal overdose especially in the first two weeks of initial 
treatment (Miller et al., 2015). A study of fair-quality found initiation of extended-release or long-
acting opioid therapy poses a higher overdose risk compared to initiation with immediate-release 
opioids (USDHHS, 2016). An evidence review also showed that extended-release and long-
acting opioids were no safer or more effective than immediate-release opioids. In fact, the same 
study showed intermediate-release opioids posed no more threat of misuse than time-scheduled, 
continuous use of extended-release and long-acting opioids (USDHHS, 2016). Extended-release 
opioids may seem worthwhile and an easy solution for certain individuals but extended-release 
produced no differences in pain or function outcomes over a one-year period in comparison to 
immediate-release opioids (USDHHS, 2016). Initiation of opioids in chronic pain management 
should start with immediate-release opioids. Fair evidence supports long-acting in certain 
circumstances accompanied with intractable severe pain that has failed treatment with short-
acting opioids (Manchikanti et al. 2012). The need for extended-release opioids include: pain 
that demands daily around the clock coverage, and cases where long-term immediate-release and 
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non-opioid treatments have failed or are not tolerated (USDHHS, 2016). Determining what 
works best for the patient in reducing pain and improving quality of life is important. 
Tapering opioids for decreased dosages or discontinuation needs special attention as it 
poses risk for withdrawal symptoms and overdose (USDHHS, 2016). Tapering rates should be 
driven by the reason for discontinuation of the opioid, for example faster tapering would 
accompany psychiatric disorders, worry for overdose versus a slower tapering rate due to failure 
of pain relief (Chou et al., 2014). Tapering opioids should start with less than or equal to 10% of 
the original dose per week to a more rapid reduction of 25-30% reduction every few days. 
Assessing the patient’s quality of life and pain status during tapering efforts should be done at 
each visit (AMDG, 2015; USDHHS, 2016). Titration of long-acting opioids must be done with 
caution reducing risk of withdrawal symptoms and overdose (Manchikanti et al., 2012). 
Urine Drug Testing  
Two types of drug screening tools exist that detect drugs in the system: urine and blood. 
The major difference is blood notifies the clinician what the patient has in his/her system and 
urine conveys what was in their system. It is important for clinicians to identify unique 
characteristic to each laboratory test. Urine drug screening is found to be more useful when 
monitoring long-term opioid therapy (Owen, Burton, Schade, & Passik, 2012).  False readings 
with immunoassay urine drug testing are common and results should be evaluated with caution 
(Denenberg & Curtiss, 2016). If suspicious of false readings, drug-specific gas chromatography 
mass spectrometry may be more confirmatory.   
Evidence supports urine drug screening used for risk-assessment, compliance, and to aid 
in reducing abuse potential (AAPM, 2013; Currow et al., 2016). When used appropriately, urine 
drug tests may identify that the individual does not know how to take the medication as 
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prescribed. Urine tests may also indicate when a patient is non-adherent to the long-term pain 
management plan, diversion is taking place, an unreported lost or stolen medication, and self-
treatment of poorly controlled pain when screening is negative. When screening is positive for 
appropriate substances, adherence is noted. Urine drug screening can be found positive for other 
substances not prescribed displaying use of illicit or non-prescription drugs, drug abuse or 
addiction, aberrant behavior, and psychological issues (Chou et al., 2014; Denenberg & Curtiss, 
2016; Owen et al., 2012). 
Good evidence supports initiation of urine drug testing prior to initiation of long-term 
opioid therapy. Subsequent monitoring for adherence which is shown to decrease drug abuse and 
illicit drug use during chronic pain management (Manchikanti et al., 2012). Urine drug testing 
should be performed prior to initiation of long-term opioid therapy in every individual and at 
least annually thereafter (USDHHS, 2016). Urine drug screening may also be performed at any 
point in therapy based on provider suspicion of non-compliance, diversion, or aberrant behavior. 
Although research is consistent regarding using urine drug testing as a monitoring tool, 
inconsistencies exist as to how often subsequent screening should be performed after the initial 
screening. Random and unpredictable intervals of urine drug tests have an advantage over pre-
scheduled screening when there are questionable aberrant behaviors. Regularly scheduled urine 
drug screening for low risk individuals confirms adherence. Patients anticipating a urine drug 
screen may change behaviors short-term to improve outcomes of screening test (Chou et al., 
2014). 
Pill Counts 
Monitoring adherence can also be done through regular or randomized pill counts. 
Incorrect pill counts may reveal nonadherence, indicate financial difficulties purchasing the 
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medication, misunderstanding of the care plan, misuse, diversion, or taking too much due to 
increasing pain (Denenberg & Curtiss, 2016). Although pill counts may improve compliance 
rates of patient on long-term opioid therapy, there is a lack of evidence supporting pill counting 
in practice. Only one guideline used pill counting as a tool to monitor adherence (Chou et. al, 
2014). Pill counting is an area that needs further research and discussion prior to determining its 
effects on adherence and practice.  
Pharmacy Checks  
Prescription Drug Monitoring Programs provide insight into opioid therapy compliance 
(AAPM, 2013). Along with urine drug testing, pharmacy checks may identify at-risk individuals 
for opioid misuse, overdose, and flag healthcare providers for stricter monitoring or customized 
interventions (Baumblatt et al., 2014). PDMP is an electronic catalog allowing clinicians access 
to when, where, and by whom prescriptions are dispensed for an individual (Denenberg & 
Curtiss, 2016).  
 Through PDMPs, identification of prescriptions from multiple doctors, filling of these 
prescriptions at multiple pharmacies, high total daily opioid dosages prescribed, or dangerous 
drug combinations being prescribed is possible (USDHHS, 2016). Gomez et al. (2011) found 
that deaths related to opioids occurred more often in individuals getting their prescriptions from 
multiple doctors and pharmacies. Ultimately, PDMPs aid in identifying risk factors relating to 
fatal overdoses (CDC, 2012). PMDPs also reduce doctor shopping, prescription drug abuse and 
adherence monitoring by providing evidence of noncompliance and prescription drug abuse 
(Manchikanti et al., 2012).  
 As with urine drug testing, the literature varies regarding recommended frequency of 
PDMP checks (Denenberg & Curtiss, 2016). The CDC guideline suggests checking PDMP prior 
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to initiation of chronic opioid therapy, at least every three months, but best if done at each visit 
(USDHHS, 2016). Chou et al. (2014) and AMDG (2015) agree that PDMP checks should 
increase in frequency with high-risk patients. Clinicians better understand an individual’s 
prescription behaviors when provided PDMP information (USDHHS, 2016).  
Contracts  
Contract or opioid agreements are highlighted throughout literature for long-term opioid 
therapy for chronic pain management (Denenberg & Curtiss, 2016). Pain contracts are written 
agreements binding a patient to follow specific terms laid out by a provider. Effectiveness of 
pain agreements or contracts have not been well studied for use in chronic pain management. 
Pain management guidelines and clinical experts suggest incorporating pain agreements into 
practice as a way to set boundaries, outline expectations for providers and patients, and establish 
accountability (USDHHS, 2016). Inclusion data for pain agreements or contracts include: 
receiving opioid prescriptions from one clinician, use of a single designated pharmacy, limited 
refills, no refills if prescription has been lost or stolen, medication must be taken as prescribed 
without authorization to increase dose, patient will safeguard prescribed medication at all times 
without sharing it with others, individuals will adhere to random urine drug testing, use of 
PDMPs, pill counts, and other risk management requirements. Adherence to the contract must be 
followed by individuals in order to receive and continue receiving opioid therapy (Chou et al., 
2014; Denenberg & Curtiss, 2016, NGC, 2013).  
Opioid agreement terms should be agreed upon and signed prior to initiation of opioid 
therapy. At that time, clinicians should also review treatment goals, how prescription opioids are 
to be taken, follow-up, alternatives treatment options, adjunctive therapies, potential indicators of 
tapering or discontinuation, failure to progress towards goals, adverse effects, intolerable adverse 
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effects, or serious aberrant drug related behaviors (AMDG, 2015; Chou et al., 2014; Manchikanti 
et al. 2012). Prior to initiation of opioid therapy, treatment goals should be discussed. These 
goals should be realistic for pain and function, discussing plans for discontinuation if benefits 
fail to outweigh risks. (AMDG, 2015; Chou et al., 2014; USDHHS, 2016; Hooten et al., 2013). 
Contracts provide clear written guidelines reinforcing expectations regarding safe and 
appropriate use of opioids (Chou et al., 2014). According to Manchikanti et al. (2012) fair 
evidence supports that opioid agreements decrease overuse, misuse, abuse, and diversion. 
Factors strongly associated with drug abuse, misuse, or aberrant drug-related behaviors with 
long-term opioid therapy are personal or family history of substance use disorders (Chou et al., 
2014). Prior to and intermittently throughout long-term opioid therapy, risks, realistic benefits, 
and patient and clinician responsibilities regarding pain management should be discussed 
(USDHHS, 2016). Discussing and signing an opioid contract defines patient and provider 
expectations.  
Referrals  
Chronic pain management is difficult and may require expert referrals. Clinicians may 
opt to seek consultation of pain medicine or other specialists depending on the provider’s 
comfort level, the complexity of the presenting issue, and in case of high-dose opioid therapy. 
Consultation is often justified when current pain management is not working and all other 
avenues have been explored, or in other difficult situations (AAPM, 2013; AMDG, 2015; Chou 
et al., 2014; NGC, 2013; Manchikanti et al., 2012). Other areas needing referrals or special 
consultation include providing long-term opioid therapy to individuals with a history of 
substance use disorders or comorbid psychiatric disorders (AAPM, 2013). Involving specialists 
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to aid in chronic pain management when needed optimizes outcomes of chronic pain (Hooten et 
al., 2013). 
Barriers 
Barriers that pose issues with chronic pain management and use of long-term opioid 
therapy exist. Clinicians often lack the confidence to prescribe opioids safely or in their ability to 
detect opioid drug abuse (Hagemeier, Gray, & Pack, 2013; Keller et al., 2012). Discussing the 
topic of abuse with patients, once detected, is difficult and adds to provider barriers of chronic 
pain management (USDHHS, 2016). Overall, clinicians believe that opioids can improve pain 
and quality of life, but concern over prescription drug abuse issues outweighs opioid use in 
practice (Hwang, Turner, Kruszewski, Kolodny, & Alexander, 2015). Other barriers identified in 
literature include scrutiny by regulatory agencies, fear of opioid toxicity, and being cheated by 
patients (Rosenberg, 2013). Throughout literature a general theme is reported. Clinicians feel 
there is a lack of uniformity and knowledge in use of guidelines and the risk mitigation tools in 
reducing risk of misuse (Ringwalt, Garrettson, & Alexandridis, 2014; Rosenberg, 2013; 
USDHHS, 2016). Clinicians find registering for access and logging into PDMP is cumbersome. 
The process interrupts normal work flow and increases clinical demands leading to inadequate 
time to discuss reasons for use of risk mitigation tools. Clinicians also cite interpreting and 
addressing the results of the PDMP as challenging (USDHHS, 2016; Smith et al., 2015). 
Variations in prescribing habits are related to a lack of pain management training, experience, 
and exposure to opioid related events. Repeated consultation that does not meet the patient’s 
need and a clinician’s failure to set appropriate boundaries and negotiate an alternative plan 
increases likelihood of inappropriate prescribing (Currow et al., 2016). Addressing clinician 
barriers may improve opioid prescribing and chronic pain management.  
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Gaps in Research 
Use of opioids for long-term pain management has created great challenges. Throughout 
literature there is a lack of evidence regarding how effective opioids are for treating chronic non-
cancer pain (Currow et al., 2016; CDC, 2016). Gaps in research fail to provide supporting 
evidence in use of pain management guidelines for improving pain, function, and quality of life, 
while decreasing abuse and overdose (AAPM, 2013). Guidelines have been more thoroughly 
studied in acute care settings and their effect on opioid abuse, misuse, and diversion show 
positive results (AAPM, 2013; USDHHS, 2016). Prescription drug monitoring programs at a 
state level lack assessment due to changes in prescribing habits and mortality outcomes 
(Haegerich, Paulozzi, Manns, & Jones, 2014). Reduction of opioid dosages raises concern that 
individuals may seek other forms of relief through nonprescription drugs such as heroin (Cicero, 
Ellis, & Surratt, 2012). Gaps in research identify areas lacking sufficient information to 
formulate conclusions, requiring further evaluation.  
Clinicians continue to hold concern over risks of opioid dependence and misuse 
associated with chronic non-cancer pain management. The increasing complexity to manage 
multifaceted physical and psychological needs of individuals with chronic pain alone is a 
daunting challenge. Long-term prescribing and limitations to available treatment approaches also 
hinder positive outcomes of chronic pain management (Currow et al., 2016).  Concerns multiply 
as rates of prescribed opioids continue to increase (USDHHS, 2016). As rates of prescribed 
opioids increase, so do rates of misuse and abuse (APA, 2013). As clinicians fight to improve 
pain management strategies, guidelines can provide a uniform toolkit focused on improving 
prescribing practices of providers leading to improved outcomes of chronic pain management, 
decreasing opioid misuse, and abuse.  
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Theoretical Framework  
 Theoretical framework provided guidance as a series of steps to reach a desired outcome 
(Melnyk & Fineout-Overholt, 2015). The Iowa Model (Appendix B) of Evidence-Based Practice 
provided decision making steps to guide the author through a decision-making process. The Iowa 
model contains seven important steps guiding implementation of evidence-based practice: 
identify triggers, clinical application, organizational priorities, forming a team, piloting a practice 
change, evaluating the pilot, evaluating practice changes, and dissemination of results. Each of 
the seven components of the Iowa Model were further broken down and used. Approval to use 
the Iowa Model was granted on December 6th, 2016 by The University of Iowa Hospitals and 
Clinics (Appendix A) (Titler et al., 2015). The steps of the Iowa Model and how it applied to the 
project are further discussed in below. 
Identified Triggers  
Identified triggers prompted questions about situations that potentiated change. 
Healthcare providers come across many barriers when managing chronic pain. One main barrier 
was opioid therapy used for chronic pain management and the potential for misuse, abuse, and 
overdose. Current opioid prescribing trends are startling. An increased awareness regarding 
opioid over-prescription and the unintended consequences of the high rates of opioid prescription 
triggered an interest in opioid therapy for chronic pain management among providers and the 
medical community. Today, differences between chronic pain management guidelines exist 
along with different recommendations on reducing over-prescribing by providers, patient misuse, 
abuse, overdose, and diversion. Providers lack experience, comfort, education, tools, and 
processes to improve prescribing habits to reduce negative behaviors associated with long-term 
opioid therapy.  
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Organizational Priorities 
Looking at what an organization deemed important provided support and the means to 
implement the project. In March 2016, the CDC released a new set of guidelines for chronic pain 
management with a focus on long-term opioid therapy. The CDC issued these guidelines to aid 
in decreasing opioid misuse, abuse, overdose by patients and over prescribing by providers. The 
guidelines are a combination of strategies designed to improve prescribing habits of providers 
and opioid safety for patients on long-term opioid therapy. The project was implemented in rural 
North Dakota, at four Coal Country Community Health Center facilities. The clinic’s medical 
director expressed concern about current opioid prescribing practices of providers at Coal 
Country Community Health Center along with an increased population of chronic pain patients 
associated with economic changes in northwestern North Dakota. Implementation of key 
strategies targeted helping providers improve prescribing habits and aided in decreasing 
destructive opioid behaviors. These strategies included maximizing PDMP use, use of urine drug 
screens, and calculating daily MME, and easy identification of chronic pain management patients 
in the electronic health record (EHR).  
Team Formation  
Team formation was key in successfully implementing the project. Key stakeholders 
included six individuals: a student seeking a doctor of nursing practice (DNP) degree, three 
faculty members teaching in the DNP/family nurse practitioner program, a faculty member to 
serve as graduate appointee, and the rural clinic medical director. Team members had an interest 
in the dissertation project topic, and each member played a key role. The DNP student led project 
development, explored ideas for practice improvement, researched up-to-date literature, 
collaborated with team members, implemented the project, evaluated outcomes, and 
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disseminated findings. Each faculty member brought something special to the table. The 
committee chair provided support throughout the dissertation process, provided advice to the 
student regarding the development, implementation, evaluation of the project and guided 
changes throughout the process. The remaining two School of Nursing faculty members, along 
with a graduate appointed faculty provided an alternative perspective to the project and made 
suggestions of possible ways to improve the project that had not been considered. The graduate 
appointed faculty held strong ties to economics and statistical analysis. The graduate appointed 
team member was a strong asset in data collection, organization, and presentation. The medical 
director, director of clinical operations, director of patient care and innovation, director of 
nursing, quality coordinator, and information technology personnel of the rural clinic helped 
facilitate the project in the clinical setting, acted as a liaison to clinic faculty members and 
provided access to facility resources needed throughout the project. Key team members provided 
feedback on corrections prior to the proposal and final defense. Collectively the team approved 
and supported the project development and implementation.  
Research and Literature  
 Explored current literature and evidence-based guidelines provided a foundation for the 
improvement project. The section a review of literature provided a detailed synthesis and 
evaluation of current literature and evidence-based guidelines. The literature presented gaps that 
need further evaluation. The main gap in evidence involved application of the guidelines. There 
are no strong studies for the use of guidelines in improving prescribing practices, decreasing 
misuse, abuse, and overdose of opioid prescription drugs (AAPM, 2013). Chronic pain 
management guidelines lacked evidence in ambulatory care, most of the interventions within the 
guidelines had strong supporting evidence for improving prescribing behaviors aimed at 
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reducing abuse, misuse, and overdose. Therefore, the project provided clinicians with 
interventions aimed at improving prescribing habits in an effort to reduce risk of long term 
opioid use.  
Piloted Practice Change  
Key objectives were identified for the project focused on piloting change. These 
objectives provided the project a foundation and focus (Melnyk & Fineout-Overholt, 2015). The 
objectives led to interventions to be carried out. These objectives included:  
1.   Provide education regarding current chronic pain management recommendations and 
accepted best practices from the 2016 CDC guidelines for: 
a.   PDMP use 
b.   Urine drug screens 
c.   MME dosing 
d.   Pain contracts  
2.   Flag all patients on a pain contract within the EHR using a uniform system.  
3.   Identify all patients without a pain contract who have been prescribed opioids ≥ 3 months 
and enroll identified patients in a pain contract over a 4-month period.  
4.   Determine all patients who have been prescribed opioids ≥ 3 months and who are receiving 
doses that place them at increased risk (patients prescribed doses ≥ 50 MME per day and 
prescribed ≥ 90 MME per day). Develop strategies to reduce risk associated with upper 
daily limits of opioids.  
5.   Develop sustainability practices to ensure compliance and continued monitoring of 
implemented recommendations for chronic pain management patients upon completion of 
project.  
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The pilot study allowed time for identifying changes or adjustments needed to increase 
project success. New barriers were found as road blocks throughout the process. The pilot study 
allowed time for overcoming these barriers to fulfill the objectives.  
Evaluated Practice Changes  
Once the program had been piloted, members of the team evaluated the outcomes. The 
evaluation process consisted of measuring and organizing statistical data of the designated 
measurable outcomes. Evaluation was an important step of the process and determined the 
success of each intervention. Evaluation defined and identified possible areas needing change 
and drove project improvements that could be made. Through evaluation the project was 
completed and provided data for dissemination. 
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CHAPTER THREE. PROJECT DESCRIPTION 
Project Design 
 Proper design is essential to project success. The CDC guideline on chronic pain 
management released at the beginning of 2016 was used as a blueprint for the project. The goal 
was to reduce over-prescribing of opioids, improve patient adherence and pain management, and 
reduce the risk of long term opioid use (CDC, 2016). The author met with Dr. Aaron Garman, 
medical director of Coal Country Community Health Center (CCCHC) and he had expressed 
interest in a project that brought elements of the new CDC guideline into practice. CCCHC had 
identified provider prescribing practices, increased opioid prescriptions, and opioid overuse in 
the community as a major concern that needed attention.  
Objective One 
 Objective one consisted of providing education to providers and clinic staff regarding 
current chronic pain management recommendations and accepted best practices from the 2016 
CDC guidelines on PDMP use, UDS use, MME dosing, and pain contracts. An education session 
including a presentation was set up on August 30, 2017 to provide education regarding CDC 
guideline elements and current recommendations. Providers, nursing staff, and certified aids 
were invited to the education session.  The session was made mandatory for all patient-care 
employees by the medical director. Education specifically highlighted the importance of the 
prescription drug monitoring program, urine drug screening, pain contracts, upper limits of daily 
morphine milligram equivalence and calculation tools to improve prescribing practices, all with a 
focus on risk reduction strategies. Contributing to provider buy-in, the author was introduced at 
the education session by the medical director of Coal Country Community Health Center. The 
medical director discussed the projects importance and impact on the clinics. Time provided at 
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the end of the education session allowed providers and staff to share any feedback and further 
discuss chronic pain management. Most of the questions and feedback included positive thoughts 
and feelings about the project. The providers expressed excitement in additions to the EHR that 
would make pain management easier for them. A laminated copy of an algorithm based upon the 
CDC guideline (Appendix C) and pre-calculated MME doses for popular opioids (Appendix D) 
was provided to all clinicians and placed in a designated area within the clinic that provides 
clinicians with easy access to the references.  
A post-education session questionnaire was given to all providers (Appendix E). The 
questionnaire focused on current understanding of information provided during the education 
session. Objective one also set a baseline on how providers use the current recommendations and 
the best practices that were reviewed during the education session, specifically observing use of 
the prescription drug monitoring program and urine drug screens.  
Objective Two 
 Meeting objective two included identifying current patients with existing pain contracts 
within the EHR. A flag “CS Consent” standing for controlled substance consent was developed 
in collaboration with informational technology services (ITS). Implementation of the flagging 
system into the EHR was accomplished by adding “CS Consent- consent initiation date” to the 
face sheet under the patient alert notes section. The alert notes section is found next to the 
patient’s problem list, allergies, and medication list, providing simple access to important 
information.   
Objective Three 
Objective three identified all individuals who were prescribed narcotics for ≥ 3 months 
and determined if the identified individuals were enrolled in a pain contract. Data was pulled 
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with the quality management program from the EHR. Once a list of names was acquired a chart 
audit was performed; looking at the duration of time, ≥ 3 months, the individual has been 
prescribed a narcotic. Once individuals were identified, a list of patient names were provided to 
primary care providers and the nurse was also flagged in the EHR about pain contract eligible 
patients. Nursing staff and other providers were consulted prior to implementation to provide 
input regarding how to best integrate the process of completing patient pain contracts seamlessly 
into the flow of the clinic. Providers were encouraged to place eligible individuals on a pain 
management contract and flag the pain contract patients in the EHR.  
Objective Four 
The goal of objective four was to determine patients who were prescribed opioids ≥ 3 
months and received doses, ≥ 50 MME and ≥ 90 MME per day, that place them at an increased 
risk for poor outcomes. Objective four also required development of strategies to reduce 
associated risks of daily opioid upper limit doses. Objective four was met by compiling a list of 
all current and potential pain management patients. Each patients chart was audited for MME 
dosing. The author built a list of patients receiving doses which increase opioid overdose risk: ≥ 
50 MME dosing per day and ≥ 90 MME dosing per day. The list was provided to each primary 
care provider. Education on steps to take for patients exceeding ≥ 50 and ≥ 90 MME dosing per 
day was provided in the education session of objective one. A quick reference sheet outlining the 
steps to take for identified patients was provided to all clinicians (Appendix F).  
Objective Five 
Objective five involved development of sustainability practices to ensure compliance and 
continued monitoring of implemented recommendations for chronic pain management patients. 
The quality coordinator was designated to take responsibility to ensure providers compliance of 
 39 
appropriate use of PDMP, urine drug screens, and MME dosing for chronic pain management. 
The quality coordinator will work closely with the director of patient care and innovation to set 
forth future interventions for providers to meet recommendations. The author provided clinicians 
with tools needed for project sustainability including:  
•   education on chronic pain management recommendations and accepted best practices 
•    integrating a flagging system into the EHR 
•   use of pain contracts 
•   distributing laminated copies of a chronic pain management algorithm, commonly 
prescribed opioid medication converted into MME daily dosing ≥ 50 MME and ≥ 90 
MME, and a quick reference of steps to take when patients exceed 50 MME daily and 90 
MME daily  
Follow-up  
 Project sustainability and system change can be challenging.  System change and 
sustainability can be encouraged through provider participation and feedback on project pros and 
cons. Once identified by the author, suggested improvements provided project enhancement.  
The author designated an individual at each clinic to be a liaison and communicate 
challenges and identify processes of the project that were working well and not working well. 
The designated staff was contacted monthly by the author to ensure open communication. 
Academic detailing was performed at the two-month mark. Academic detailing included the 
author being physically present at each facility and visiting with all staff members about the 
project processes, pros, cons, and possible improvements.  
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Project Timeline  
March: 
•   Discuss the projected plans with the medical director of the clinic  
•   Determine the requirements of gaining access to the EMR and patient records  
•   Determine additional requirements that may be needed to fulfill project objectives  
May:  
•   Proposal meeting 
July: 
•   IRB application  
August: 
•   Determine a date, time, and location of the education session  
•   Complete initial chart audit and data collection  
November:  
•   Check-in with facility and determine how processes are working 
January: 
•   Post chart review and data collection 
•   Data evaluation  
•   Write final dissertation 
March 
•   Final dissertation defense  
Resources  
 For this project to work, many factors came into play. The project required key 
stakeholders, including providers, nurses, certified aids, information technology, and 
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receptionists. The author maintained close contact with the medical director of the clinic, director 
of clinical operations, director of patient care and innovation, quality coordinator, and the 
director of nursing throughout the implementation and evaluation process. The author gained 
access to the EHR to collect data on PDMP use and documentation, urine drug screening, and 
MME calculation and documentation. Sustainability moving forward will rely heavily on the 
education provided, provider and staff willingness, if providers find interventions beneficial, 
minimal work flow interruptions, and the anticipated importance of the topic. 
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CHAPTER FOUR. EVALUATION 
Evaluation Plan 
 Evaluation plays an important role in improving practice. Data was collected for each 
objective upon completion of the project. Evaluation of data provided insight into the success of 
the project.  
 Initially, four Coal Country Community Health Center clinics were supposed to be 
included in the project. The project was not initiated into one of the clinics due to uncontrollable 
circumstances relating to staffing limitations. Data regarding the non-participatory clinic was not 
included in the project. The remaining three clinics participated in the project and continued with 
implementation of objectives.  
 The project design and evaluation of the practice improvement project incorporated use 
of the Logic Model (Figure 1) (W.K. Kellogg Foundation, 2004).  
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Situation 
•   In 2012, 259 million opioid pain medication prescriptions were provided by health care 
providers. Half of the opioid related overdose deaths are a result of prescription opioids (CDC, 
2014) 
•   In March 2016, the Centers for Disease Control and Prevention (CDC) released a new Chronic 
Pain Management Guideline to aid in improving provider’s prescribing practices and reduce 
overuse and abuse of opioids (USDHHS, 2016)  
 
Priorities 
•   Improve opioid prescribing practices of primary care providers for chronic pain management 
•   Reduce the number of opioids prescribed for chronic pain management 
•   Reduce the dosage of opioids prescribed for chronic pain management 
•   Reduce misuse and overdose of opioids by patients with chronic pain secondary to improving 
provider prescribing habits 
 
 
Inputs 
•   NDSU DNP Student & Committee 
•   CDC Chronic Pain Guidelines 
•   Key Stakeholders (Medical director, director of clinical operations, director of patient care and 
innovation, quality coordinator, and director of nursing) 
•   Primary Care Providers 
•   Information Technology department  
 
 
 
Activities 
•   Provide education on current chronic pain management recommendations and accepted best 
practices from the 2016 CDC guideline for PDMP use, UDS, MME dosing, and Pain contracts  
•   Flag all patients on a pain contract within the EHR using a uniform system 
•   Identify all patients without a pain contract who have been prescribed opioids ≥ 3 months, and 
enroll identified patients over a 4-month period  
•   Determine patients prescribed opioids ≥ 3 months and receiving doses placing them at an 
increased risk (taking ≥ 50 MME & ≥ 90 MME per day) and develop strategies to reduce risk 
•   Develop sustainability practices to ensure compliance and continued monitoring of 
implemented recommendations for chronic pain management patients upon completion of the 
project 
 
 
Outputs 
•   Post education questionnaire showing provider understanding of chronic pain management 
using opioids  
•   Chart audit showing improvement in PDMP and UDS use  
•   Chart audit showing all patients on a pain contract have been flagged within the EHR 
•   Chart audit showing the number of patients who were placed on a pain contract after being 
identified as eligible 
•   Chart audit showing the recommended steps provided during the education session were 
implemented for patients taking ≥50 MME per day and ≥ 90 MME per day 
Outcomes 
(Short Term) 
•   Providers have tools within the EHR and strategies to help them improve chronic pain 
management with opioids  
•   Providers recognize and use strategies to improve prescribing practices of opioids for chronic 
pain discussed in the 2016 CDC guideline 
Outcomes 
(Long Term) 
•   Continued use of tools provided in the EHR and provided strategies to improve chronic pain 
management  
•   Continued monitoring of implemented strategies for chronic pain management patients  
 
Impact 
•   Expand provider knowledge in chronic pain management with opioids 
•   Improve opioid prescribing practices of Primary Care Providers for chronic pain 
management 
•   Improve patient safety by decreasing misuse and overdose while optimizing chronic pain 
management 
Figure 1. Logic Model 
Objective One 
Evaluation of the CDC guidelines and best practices was initiated by a post-education 
questionnaire. Data from the post-education evaluation was collected from providers. The 
questionnaire evaluated the overall knowledge and understanding on chronic pain management 
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recommendations and accepted best practices. Additional evaluation components included 
tracking rates for UDS and PDMP use, which included data collection and a chart review on 
individuals enrolled in the opioid management program by 12 different providers.  
Urine drug screen and PDMP data was more challenging to collect than originally 
anticipated. Data on UDS annual review was supposed to be collected through IT reports, but the 
current system was unable to separate out pain contract data. Therefore, 34 charts were audited 
looking at urine drug screens collected on all current chronic pain management patients and 11 
charts were audited on urine drug screens performed on patients who were eligible and enrolled 
on a pain contract since initiation of the project. The second area of focus identified if providers 
were reviewing the PDMP at least every 3 months.  
Upon development of the project, key stake holders were under the impression PDMP 
reports were being scanned into the patient’s chart upon review. During the initial chart audit, the 
author discovered no PDMP reports had been scanned into the EHR. The director of patient care 
and innovation identified a need for simpler PDMP documentation. The key stake holders 
initiated an update to the EHR to place a check box reading PDMP reviewed that would be 
placed in the provider’s final dictation. The implementation of the checkbox was not completed 
until the end of November. Data collection included the number of documented UDS and PDMP 
checks at the beginning and after four months of the intervention. The data will be compared to 
determine if UDS and PDMP use has improved.  
Objective Two 
 Identification of all patients on a pain contract within the EHR was evaluated. The 
objective evaluation included developing a flagging system for the EHR such as “CS Consent” 
placed on the patient’s face sheet. Development was done in collaboration with ITS. Tracking 
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the completed number of charts flagged with “CS Consent” on the face sheet concluded 
evaluation of objective two. 
Objective Three 
Evaluation of objective three was completed by determining the number of patients who 
were enrolled in a pain contract from those patients identified at the beginning who met chronic 
pain management eligibility. Individuals were identified and enrolled throughout the four-month 
project. At the completion of the four-month phase, data was again collected through a chart 
audit on all eligible individuals to determine the number of patients enrolled on a pain contract 
and flagged within the EHR. 
Objective Four  
Chart audits were performed to evaluate objective four. The chart audits identified 
patients taking ≥ 50 MME per day and ≥ 90 MME per day. The audit determined if 
recommended steps provided in the education session and on the quick reference sheet were 
implemented.  
Objective Five 
 The author evaluated the completion of tools implemented for project sustainability 
including: education on chronic pain management recommendations and accepted best practices, 
integrating a flagging system into the EHR, pain contracts, and distributing laminated copies of a 
chronic pain management algorithm with commonly prescribed opioid medication converted into 
MME daily dosing meeting 50 MME and 90 MME, and a quick reference of steps to take when 
patients exceed 50 MME and 90 MME daily.  
The author reviewed the monitoring process with the quality coordinator assigned to 
monitor chronic pain management recommendations. The quality coordinator will perform a 
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chart audit on 10 randomized charts every six months. Due to the time required to complete a 
chart audit along with other daily duties requiring completion by the quality coordinator, 10 
biannual charts audits were recommended by the quality coordinator to be realistic goal.  The 
data collected from the chart audit will include the following: PDMP has been checked at least 
every three months, urine drug screens are being checked at least annually, and MME dosing 
remains at or below 50 MME per day. For cases where dosing remains ≥ 50 MME and ≥90 
MME per day, rationale clearly that dosing benefits outweigh the risks. The quality coordinator 
was responsible and will continue to identify that the laminated chronic pain management 
algorithms and common MME opioid dosing conversions are in their designated locations.  
The overall goal for each objective was to improve the criteria elements in comparison to 
pre-project data. Therefore, the author will expect to see an increased knowledge and 
understanding of chronic pain management, improvement in PDMP access for providers and 
delegates, improved rates of UDS use, and utilization of strategies to improve chronic opioid 
pain management prescribing.  
Protection of Human Subjects 
 Protecting human subjects is important for maintaining the integrity of the practice 
improvement project. The project poses minimal or no violation of the Health Insurance 
Portability and Accountability Act and patient contact was not required for completion of the 
project, exposing patients to minimal or no risk. Medical records were accessed using a secure 
login, in a private area, and patient information was only read by the author and not shared with 
other team members. The exempt IRB approval process best fit the project as direct contact with 
patients was not necessary.  
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 Research was limited to individuals 18 years and older that were on non-cancer chronic 
opioid pain management. The process of data collection was obtained from the EHR on data, 
documents, records, and results. Information collected did not include patient identifiers such as 
but not limited to name, age, date of birth, and medical record numbers. Patient’s risk was 
minimal, and the goal was to improve safe prescribing practices by providers. The goal of the 
project was aimed at improving prescribing practices, recognizing dangerous prescribing 
practices by providers, and provider recognition of patient adherence to chronic opioid pain 
management. 
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CHAPTER FIVE. RESULTS  
Success of the project can be contributed to the time and effort spent on development, 
implementation and evaluation. The project involved building interventions, analyzing research, 
and evaluating results. Evaluation of the project looked at strategies aimed at improving 
prescribing habits of rural primary care providers managing chronic pain with opioids. Three 
clinics of the same organization were included in the project. Project parameters were set by the 
author using evidence-based research for opioid use and chronic pain management. Five pieces 
of data were analyzed and evaluated looking for improved practice of chronic pain management 
with opioids. The data collection included:  
•   the number of pain contract patients and how many were flagged in the EHR 
•   determine the number of eligible pain contract patients that were enrolled in a pain 
contract and flagged in the EHR 
•   determine the number of annual urine drug screens done before and after initiation of the 
project 
•   the number of prescription drug monitoring program reports reviewed at least every three 
months before and after initiation of the project 
•   discussing with the quality coordinator how to complete a chart audit for continued data 
monitoring 
An initial chart review was performed on patients that IT identified as being prescribed 
opioids. Data was collected and placed into a flowsheet. At the completion of four months a 
chart review was performed on appropriate charts to determine if project parameters had 
improved.  
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Post-Education Provider Questionnaire Results 
A post-education questionnaire (Appendix E) was provided to 10 clinicians who attended 
the education session on August 30, 2017. After the education session was completed, an open 
discussion was held between the providers and remaining 37 clinical staff in attendance. Nine of 
the 10 providers returned the questionnaire with responses. The remaining provider in attendance 
and the remaining two providers not in attendance did receive but did not return the 
questionnaire. Following are the questions and the providers’ responses. 
 The following (Table 1) represent the questions from the post education questionnaire. 
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Table 1 
Post Education Questionnaire  
Questionnaire Responses: Themes and Associated Questions  
Please answer the 
following questions based 
on the presented education              
Questions 1-3 
 
1.   Did this session meet your educational needs?  
2.   Did the information presented reinforce and/or improve 
your current skills? 
3.   Did the information presented provide new 
ideas/information you expect to use?  
 
Please rate the projected 
impact of this education 
activity on your 
competence, performance, 
and/or patient outcomes                             
Questions 4-6 
 
4.   This activity increased my competence? 
5.   This activity will improve my performance? 
6.   This activity will improve my patient’s outcomes? 
 
 
Answer the following 
questions regarding best 
practice for chronic opioid 
management       
Questions 7-14 
 
7.   What is your comfort level of caring for a chronic pain 
management patient? 
8.   Rate your understanding of who should be placed on a 
pain contract?  
9.   Rate your understanding on the process to follow to 
place a patient on a pain management contract?  
10.  Rate your understanding of how often the PDMP 
should be checked on chronic pain management 
patients?  
11.  Rate your understanding of how often UDS's should be 
performed on chronic pain management patients?  
12.  What is your understanding on how to care for patients 
that exceed 50 MME per day?  
13.  Rate your understanding on how to care for patients 
that exceed 90 MME per day? 
14.  Rate your understanding of the recommendations 
provided by the 2016 CDC guideline on chronic pain 
management? 
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The first three questions focused on the education presented by the author. Responses to 
questions one through three were based on a three-part response including no, somewhat, and 
yes.  
The following graph (Figure 2) represents the answers to questions 1, 2, and 3. 
 
Figure 2. Questionnaire Results: Questions 1, 2, 3 
Questions four through six focused on the projected impact the education had on their 
competence, performance, and/or patient outcomes. Responses to questions four through six 
were based on a three-part response including no increase, moderate increase, and great increase.  
The following graph (Figure 3) represents the answers to questions 4, 5, and 6.  
1
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Post-­‐Education  Questionnaire
Question  1-­‐3
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No Somewhat Yes
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Figure 3. Questionnaire Results: Questions 4, 5, 6 
Questions seven through fourteen were in regard to the best practices for chronic opioid 
management. Responses to questions seven through 14 were based on a five-part response 
including very poor, poor, acceptable, good, and very good.  
The following graph (Figure 4) represents the answers to questions 7 through 14.  
 
Figure 4. Questionnaire Results: Questions 7, 8, 9, 10, 11, 12, 13, 14 
3 2 3
6 7 6
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 53 
The final three questions on the questionnaire were open ended. One question focused on 
the education provided and areas of concern when treating chronic pain management.  
 The following graph (Table 2) represents the answers to questions 15 through 16. 
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Table 2  
Questionnaire Results: Questions 15, 16, 17 
 
Initial Chart Review Results  
 The author performed an initial chart review in August 2017 prior to the education 
session. The initial chart review included 364 charts of patients who were being prescribed 
opioids. Data collection identified if the patients were prescribed opioids for ≥ 3 months and if 
they were on a pain contract. Forty-two patients were found to have a pain contract and 17 more 
Open Ended Questionnaire Responses  
Question 15 Question 16 Question 17  
Based on the education provided, 
what areas of concern do you have 
in treating chronic pain 
management patients? 
Based on the education provided, 
what issues should the system 
address to help you improve 
management of chronic pain 
patients? 
What are the top three barriers to 
managing pain? 
Contributing to opioid dependence  Provide an easy spot to see a patient 
is on a pain contract 
Trouble with subjective symptoms 
leading to a treatment plan 
 
Addressing high MME doses, 
reducing doses, and discontinuing 
doses with patients  
Implement reminders that patients are 
on contracts, identify if they have 
been dismissed, if a UDS is due, and 
a program that calculates MME 
dosing 
 
Troubles trusting patients 
Non-compliant patients  EMR alerts for patients eligible on a 
pain contract 
 
Difficult to confront patients 
Lack of resources for consults, pain 
specialists, mental health care  
 
Improved EMR charting  Stigma associated with pain 
medication use 
Lack of experience  Key reminders for checking records, 
doses, and drug screens 
 
Patient compliance 
Effectively offer alternatives when 
appropriate 
 
 Psychosocial component of pain 
management 
Time available to spend with 
patients  
 
 Lack of consistency across 
different providers 
Pain is subjective  
 
  
Patients that become addicted are 
manipulative 
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patients were identified as being eligible for a pain contract. The 42 charts reviewed of patients 
previously identified on a pain contract revealed zero patients had a PDMP report scanned into 
the EHR. The chart identified nine of the 42 patients or 21% on a pain contract had a UDS 
performed in the past year. Morphine milligram equivalence was evaluated for all patients on a 
pain contract. Seven of the 42 pain-contract patients or 16.7% were being prescribed dosages ≥ 
50 MME per day and nine of 42 or 21% were being prescribed dosages ≥ 90 MME per day. Data 
analysis was also performed on patients who were eligible for pain contracts. Three of the 17 or 
17.6% of patients were being prescribed ≥ 50 MME per day and five of 17 or 29% were being 
prescribed ≥ 90 MME per day.  
 The chart audits were completed at the Beulah CCCHC site on a provided desktop 
computer. The author was provided a username and password to access the EHR. The data was 
collected and recorded in OneDrive Business and only accessed through the clinics computer. No 
patient sensitive data was taken from the clinical site. Protection of data was assured throughout 
the project.  
Final Chart Review Results  
 The final chart review was moved from six months to four months with approval from 
the project committee. This change addressed time constraints of the project due to delays in IRB 
approval and scheduling with the clinics to initiate the project. The final chart review was 
completed the first week of January 2018. The same data was reviewed and analyzed as the 
initial chart review.  
 The initial 42 patients identified on pain contracts were evaluated and three were placed 
on the facilities restricted list, three had their pain contract discontinued, and two were no longer 
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being prescribed opioids because they moved out of state. Thirty-four of the original 42 
remained on a pain contract.  
 The following graph (Figure 5) represents the post-implementation results of the patients 
previously on a pain contract. 
 
Figure 5. Post-implementation Results of Previously Identified Pain Contract Patients  
 The following graph (Figure 6) represents the post-implementation results of the patients 
meeting pain contract eligibility.  
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Figure 6. Post-implementation Results of Patients Meeting Pain Contract Eligibility 
At the end of the project 45 patients had a pain contract, combining the 34 patients who 
initially were on a pain contract and the 11 eligible patients who were placed on a pain contract.  
 The following tables (Table 3 and 4) represent PDMP Review and UDS results.  
Table 3 
Pre and Post Implementation Comparison of Clinical Interventions for All Patients in a Pain 
Contract  
 Pre-Implementation 
(n=42) 
 Post-Implementation  
(n-45) 
  
Variable Value  Value  Percentage Change 
PDMP Review  0  18  N/A 
UDS  9  15  66.7% 
 
  
11
2
2
2
Pain  Contract  Eligibility
Number  of  Patients  Placed  on  a  Pain  Contract  After
Identification
Number  of  Eligible  Patients  Who  Where  Not  Placed
on  a  Pain  Contract
Number  of  Eligible  Patients  Who  Where  Not  Placed
on  a  Pain  Contract
(Clinician  provided  documentation  explaining  why
patient  was  not  placed  on  pain  contract,  therapy
continued  with  PRN  dosing)
Number  of  Eligible  Patients  with  Discontinued  Opioid
Therapy
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Table 4 
Pre and Post Implementation Comparison of Clinical Interventions for Patients Previously in a 
Pain Contract and Newly Enrolled in a Pain Contract 
   Previously on a Pain Contract 
(n=34) 
  Newly Placed on a Pain Contract 
(n=11) 
Variable  n Value  n Value 
PDMP Review   11 32.35%  7 63.64% 
UDS  8 23.53%  7 63.64% 
 
The following are graphs (Figure 7 and 8) represent MME daily dosing interventions.  
 
Figure 7. Pre and Post Implementation Results of Patients Prescribed ≥ 50 Morphine Milligram 
Equivalence per Day 
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Figure 8. Pre and Post Implementation Results of Patients Prescribed ≥ 90 Morphine Milligram 
Equivalence per Day 
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CHAPTER SIX. DISCUSSION AND RECOMMENDATIONS  
 The practice improvement project identified the opportunity for potential improvement in 
both prescribing practices and chronic pain management of opioids. Findings showed providers 
increased their knowledge and comfort in using evidence-based practice guidelines. Based on the 
post-education questionnaire, providers identified lack of comfort in calculating safe MME daily 
doses and caring for patients with at-risk doses. Continuing education focused on MME dose 
calculation and patient care for high-risk doses could potentially overcome this barrier. 
Discussion with individual providers revealed significant interest and need for improved 
opioid prescribing and monitoring strategies concerning chronic pain management patients. The 
chart review revealed that four of the providers followed all recommendations and accepted best 
practices fully. The remaining providers followed only certain elements while others did not 
follow any elements of the recommendations and accepted best practices. After expressing 
concerns about prescribing, some providers showed improved knowledge and comfort in use of 
guidelines but continued their current practice. Further education and intervention may help 
overcome this hurdle. A shift in culture at the clinic with other providers following 
recommendations may also lead to change in practice.  
Results showed that many providers improved evidence-based monitoring strategies, 
which were designed to improve provider prescribing practices and reduce the risk of long term 
opioid use. Although improved, further intervention could build on current monitoring strategies 
leading to increased adherence by providers. Interventions may include further education or EHR 
based reminders for checking PDMPs and collecting UDSs. 
Identifying patients eligible for enrollment in a pain contract was an important aspect of 
the project. The project identified patients eligible for a pain contract, based on a history of being 
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prescribed opioids ≥ 3 months. Providers demonstrated excellence in enrolling eligible patients 
in pain contracts. Results can be interpreted in different ways, but the results clearly show that 
providers understand the importance of recognizing patients using opioids long term. Results 
also show providers may be hesitant to acknowledge that monitoring strategies can promote 
positive outcomes and reduce risks associated with chronic opioid use. Further research and 
education could demonstrate and promote monitoring strategies among providers to improve 
adherence 
 EHR chart flagging was a need identified early in project development by the 
implementing facility. A universal flagging system within the EHR allowed providers to easily 
identify pain management patients. Providers said the flag became especially helpful when 
seeing another provider’s patient enrolled in a pain contract.  
Evaluation did not identify any facility specific tends in following guideline 
recommendations and accepted best practices. Individual trends and behaviors in managing 
patients with chronic pain were identified. The multi-site system used in the project provided a 
clear picture that facility trends did not disrupt the project's versatility. The project is 
generalizable to other clinical sites that will hold their own set of individual trends but is not 
limited by specific facility trends.  
Overall the project showed improvement in all interventions carried out. Further 
interventions building on the project foundation could further improve outcomes. Allowing 
providers more time to carry out interventions may be a key tool in continuation of the project. 
Further research is needed for determining if the combined interventions produce improved 
patient outcomes. 
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Project Limitations  
After initiating, implementing, and evaluating the quality improvement project, 
limitations were identified. Limitations are characteristics that impact the interpretation of 
findings (Melnyk & Fineout-Overholt, 2015). Identified limitations included UDS collection, 
clinic involvement, lack of provider initiative, non-distinguished pain management visits, patient 
limitations, shifting beliefs in pain management, and patient satisfaction scores. The limitations 
may have impacted the outcome of the project and need to be identified to better interpret results.  
A limitation of urine drugs screens was identified. The education session discussed in 
great detail when pain contract patients should have a UDS collected. A chart review identified 
that UDS collections were falling short upon initiating pain contracts except for one provider. It 
was also identified that the most patients on pain contracts for greater than a year still did not 
receive an annual UDS after education was provided. Most providers express that they relied on 
the nursing staff to look up the last UDS and notify the provider of the last collection. Urine drug 
screen use may improve with better coordination. Strategies to improve UDS completion 
include: furnishing providers and nursing staff with a reference listing the steps to take when 
placing a patient on a pain contract; and creating a yearly deferred order within the EHR as a 
reminder to complete annual UDS may have improved UDS use. 
 In relation to clinical involvement, two of the clinics showed great interest and initiative 
for the project. After evaluation of the project it was evident that third clinic did not participate in 
any of the recommended best practices, failing to enroll eligible patients on pain contracts, and 
did not respond to any of the check in opportunities. Talking to one provider individually from 
each clinic after the education session and maintaining an open line of communication may have 
helped with communication at each clinic.  
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Lack of attendance to the education session may have contributed to the project 
limitations. All of the providers who were unable to make it to the education session were 
provided a voice over power point of the education materials and the discussion that occurred 
during the education session. The two providers that did not make it to the education session 
were given the post-education questionnaire. The questionnaires were not returned. One of the 
providers did not complete the questionnaire at the education session, leaving nine respondents. 
The author tried to keep questionnaire responses anonymous in hopes of honest feedback, 
therefore making it difficult to identify and discuss returning the questionnaire. Increasing the 
number of reminder emails to all providers may have been one way to receive the additional 
questionnaires.  
Limitation incongruences between clinician’s concern of chronic pain management with 
opioids and data collected through the chart audit exist. During the education session and project 
feedback provided during monthly check-ins and the mid-point on site follow-up providers 
expressed great concern about the complexity of chronic pain management with opioids as well 
as how opioid treatment may contribute to the opioid crisis. The concern was not reflected by the 
very minimal number of individuals who were discontinued on a pain contract due to 
noncompliance with the recommended guidelines. It is possible that the lack of follow through 
with guideline recommendations and accepted best practices by a few select providers may 
reflect that they feel the recommendations will not have an impact on such a complex issue. 
Rural healthcare may be a contributing limitation. The nearest chronic pain management 
specialist to the practicing communities is 65 to 75 miles away. Providers may be hesitant to 
refer patients based on individual patient situations such as trying to accommodate transportation 
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or difficult work hours. Therefore, providers may continue managing chronic pain management 
even when they are uncomfortable.  
Patients seeking chronic pain management often present with multiple complex 
comorbidities is a distinct limitation. Pain management and pain prescriptions may be lost within 
appointments discussing other co-morbid conditions. Prescription pain medication may be 
prescribed at appointments not designated for pain management leaving little time for providers 
to discuss pain management. Lack of time leads to missed opportunities to perform and complete 
current guideline recommendations and best practices. Although it may be in the provider’s best 
interest to complete the recommendations and best practices, other comorbidities become a 
priority. Encouraging providers to make separate pain management visits may have helped this 
limitation.  
Patients present obstacles creating project limitations. Providers may perform appropriate 
chronic pain management guideline recommendations and best practices, but patients fail to 
follow through. Patients may not follow-up as recommended or comply with provider 
recommendations. Due to the short project timeline, lack of follow-up may limit providers from 
placing eligible patients on a pain contract and performing appropriate UDS and PDMP checks. 
Extending the project timeline may have allowed for improved follow through regarding 
recommendations and best practices. 
 Time may present limitations for providers. Providers expressed concern at the end of the 
education session and in the post education questionnaire that one of the main obstacles was lack 
of time. Overall, providers agreed that to properly discuss pain management, visits should be 
about an hour long and they currently are allotted 15 minutes. Inadequate time related to short 
appointment times or addressing multiple problems in one visit contributes to failed chronic 
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opioid pain management (Krebs et al., 2014). Increasing time allotment for providers, especially 
at the initial visit, would have aided with the limitation of time.  
 Cost of urine drug screens can contribute to limitations of the project. Urine drug screens 
are expensive and although the clinic changed companies to try to reduce the cost, it still seems 
to be burdensome for patients. Depending on the patient’s insurance the UDS may not be 
covered and the patient is required to pay out of pocket (USDHHS, 2016). Providers may 
hesitate to follow recommended best practices based on clinical judgement and cost of urine drug 
screens. Discussing the need for an annual UDS and the associated cost with patients upon 
initiation of the pain contract may be beneficial to practice. Urine drug screen discussions would 
allow patients time to ask questions and process the possible need to pay out of pocket prior to 
signing the contract. Removing some of the responsibility off of the provider onto the patient 
may help with the identified limitation.  
 Generational considerations may play a role in project limitations. In recent years a shift 
in perspective on pain management and use of opioids has changed. Pain management has 
changed dramatically starting in the early 1990’s when pain was being undertreated. A push for 
improved pain management initiated adding pain as the fifth vital sign. Now overtreatment of 
pain is the trend especially with opioids. In 2016, the American Academy of Family Physicians 
recommended dropping pain as the fifth vital sign in an effort to combat the opioid crisis in the 
United States (American Academy of Family Physicians [AAFP], 2016; The Joint Commission, 
2017). Providers who have been practicing since the early 90’s may present resistance as this 
shift in mentality is difficult. Further and continued education may help improve the resistance to 
change.  
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 Striving to improve patient satisfaction scores contributes to project limitations. An 
increasing emphasis has been placed on patient satisfaction scores and these scores are being 
linked to health care reimbursement. Pain management is one area that often falls short on 
patient satisfaction scores. In an attempt to improve satisfaction scores in regard to pain 
providers strive to satisfy patients reported pain. Although this cycle helps to improve patient 
satisfaction and reimbursement, it also encourages providers to prescribe opioids without limits 
to achieve unrealistic goals (Tompkins, Hobelmann, & Compton, 2017). The Centers for 
Medicare and Medicaid Services (CMS) has recently made changes to current policy by 
removing the pain management elements from the calculated payment based off the Hospital 
Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores starting the 2018 
fiscal year. Currently HCAHPS scores are used for the Hospital Value-Based Purchasing (VBP) 
Program, which provides incentive payments to acute-care facilities for Medicare beneficiaries 
provided quality care (Centers for Medicare & Medicaid Services, 2017). Change to policy 
regarding patient satisfaction scores and reimbursement would contribute to reducing the 
limitation.  
 Sample size presents as a project limitation. Although sample size is a limitation, the goal 
of the quality improvement project was not intended to generate new research. The goal of the 
project was to provide clinicians with evidence-based tools and strategies to improve prescribing 
practices and reduce risk of long term opioid therapy.   
 Project limitations are to be expected with the size of the project. Pain management 
presents a magnitude of barriers that primary care providers need to overcome. The opioid 
epidemic in the United States is driven by inappropriate prescribing of opioids by providers and 
misuse by patients. Finding a balance between managing patient’s pain and prescribing opioids 
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appropriately is challenging. A chronic pain management guideline presents a tool to improve 
provider prescribing practices through evidence-based recommendations and accepted best 
practices to reduce misuse and abuse of opioids by patients (USDHHS, 2016). Implementing 
guidelines into practice comes with its own set of challenges and limitations. Throughout the 
project steps were taken to reduce limitations including monthly emails and a midpoint check-in. 
Over the four months, providers seemed to become more receptive of the project and more 
willing to implement the chronic pain management guidelines into their practice.  
Project Site Recommendations  
 Strategies for project maintenance were built into the project objectives. The data 
analysis showed improvement in most areas of monitoring chronic pain management care. The 
two areas failing to show substantial improvement were providers following appropriate 
interventions for patients being prescribed ≥ 50 MME per day and annual urine drug screens. 
Recommendations for the facility include continued use of the 2016 CDC chronic pain 
management guideline recommendations and accepted best practices.  
The author recommended that the facility implement a nurse driven protocol for new 
chronic pain management patients taking opioids. Nurse driven protocols have shown to help 
improve standardization, communication and outcomes while reducing patient harm (Committee 
on Professional Liability & Committee on Patient Safety and Quality Improvement, 2015). The 
protocol would provide strategies for the health care team to easily identify the chronic pain 
management population and implement guideline recommendations and best practices. This 
protocol would encourage nursing staff, once a pain contract was initiated, to flag “CS Consent” 
under patient alert notes, enter an annual health maintenance reminder, collect and order a UDS 
if appropriate, check the PDMP, and calculate the MME daily dosage.  
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 Recommendations include strategies for improved collection and review of annual urine 
drug screens and continued evaluation of daily MME dosing. Initiating an annual health 
maintenance reminder for urine drug screens on all patients currently identified on a chronic pain 
management contract would help the provider (Alvandi, 2015). The reminder would eliminate 
the time it takes the provider to review charts over the last year in an attempt to figure out when a 
patient will need their annual UDS. Recommendations for a maintenance reminder for an annual 
review of the patients MME dosing would be appropriate. It may also be helpful if these two 
reminders could be grouped into one.  
Recommendations for the facility include continued work towards implementing 
evidence-based strategies and recommendations set forth by the improvement project. For further 
growth, the author recommends that the quality coordinator works closely with the director of 
patient care and innovation to build on the foundation the project has made. It would be 
important to have analyzed data pulled biannually by the quality coordinator and the progress 
shared with providers. Data analysis will allow the facility to understand where adjustments need 
to be made and where to focus further efforts. Through this process the foundation of the project 
would be strengthened and built upon for continued improvement in chronic pain management.  
Future Practice and Research Implications  
 Dissemination plays an important role in the quality improvement project. Dissemination 
is the process of distributing information broadly through multiple different structures (Melnyk, 
& Fineout-Overholt, 2015). Although the results were not complete, the project was 
disseminated through a poster presentation and a 5-minute presentation to attendants at the 2017 
North Dakota Diabetes Summit and a poster presentation at the North Dakota Nurse Practitioner 
Association Pharmacology Conference in September 2017. Results of the project were 
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disseminated to providers and supporting staff at the participating clinics quarterly meeting in 
February 2018. The author will develop a three-minute thesis video that will be used to further 
disseminate the project. A final poster will be created and presented at the Annual Research Day 
at North Dakota State University at Sanford in May 2018.  
 Project evaluation identified areas where the interventions improved chronic pain 
management, areas needing further improvement, and possible additional interventions. 
Additional interventions would build on the foundations of the project and enhance practice 
beyond the scope of the project. Continued research would contribute and shape future 
recommendations and best practices of monitoring and managing chronic pain. Further research 
on the best way to monitor morphine milligram equivalence would be beneficial. Opioid related 
overdose deaths have been linked to MME daily dosing ≥ 50 and the risk increases at ≥ 90 MME 
per day. Monitoring MME daily dosages presents many barriers and unlike PDMP and UDS 
monitoring current guidelines fail to advise monitoring recommendations (USDHHS, 2016). One 
barrier identified through the provider education questionnaire was discomfort on covering 
topics such as decreasing or eliminating opioid dosages. Further research and education on 
providing counseling to patients on high risk daily dose opioids could provide a positive impact 
on practice. Throughout research there is a lack of evidence supporting pill counts. Further 
research on pill counts could determine its benefit in further monitoring chronic pain 
management (USDHHS, 2016). Evidence highlights the lack of support contributing to the use 
of opioids and achieving pain control. Research highlights the importance of offering alternative 
and adjunctive treatment options for chronic pain, but research is lacking on what alternative 
therapies would work best for specific types of pain. Improved provider knowledge and 
strategies on improving chronic pain management are important for the advancement of 
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improving practice. Formulation of new evidence helps contribute and build on provider’s 
knowledge and practice improvement techniques.  
Opioids therapy has been overused for chronic pain management and in an effort to 
combat the opioid crisis the CDC released a new set of chronic pain management guidelines with 
a focus on use of opioid therapy (Hsu, 2017). The guidelines highlight recommendations and 
best practices when prescribing opioids for chronic pain. Although these guidelines will help 
make providers more aware and understand ways to improve prescribing practices of opioids, it 
will not solely solve the opioid epidemic. Lawsuits against providers in regard to overprescribing 
of opioids is on the rise. Implementation of the quality improvement project pushes providers in 
the right direction by building on an evidence-based foundation that will not only help improve 
practice but protect providers against lawsuit. Having evidence-based interventions that target 
prescribing and monitoring may potentially reduce the risk of litigation for providers at the 
facility if safety practices were questioned (Yang, Larochelle, & Haffajee, 2017).  
On October 26, 2017, President Donald Trump declared the opioid crisis in the United 
States a public health emergency (Johnson & Wagner, 2017). This project not only contributes to 
improving the opioid epidemic but also provides a foundation for further growth at the clinics 
where the project was implemented. The project can be adopted by primary care providers and 
built upon by other facilities. A push has been made by the federal government to curb the opioid 
epidemic. This project focuses on improved opioid prescribing practices and improved 
monitoring of chronic pain management patients. Although the project does not make a large 
impact on improving the opioid epidemic, it does contribute to the larger picture. The 
improvement project pushes for a movement and behavior towards improvement. Showing how 
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small changes can make an impact may encourage others to join the movement towards 
improving the opioid epidemic.  
Application to Other Doctor of Nursing Practice Roles  
 Implementation of a quality improvement project builds and expands upon many 
different roles within the Doctor of Nursing Practice.  During project development, scientific 
underpinnings played an important role as the author translates knowledge into new approaches 
to improve patient outcomes. Leadership played a strong role during the building, 
implementation, and evaluation of a quality improvement project. The author initiated and 
facilitated the project with a goal to promote patient safety and improve practice. Patient safety 
and practice improvement (developed through close collaboration with providers) further 
developed the leadership role. Throughout the project the author used many aspects of 
technology to aid the improvement of health outcomes. During the process, the author advocated 
for safety and improved outcomes of chronic pain management patients. DNPs are strongly 
recognized for their successful efforts in practicing health promotion. The efforts have not gone 
unnoticed as patient outcomes have improved. The project exemplifies health promotion by 
improving health outcomes through prescribing practices of providers and evidence-based 
monitoring strategies to reduce chronic opioid therapy risks. The quality improvement project 
not only provided growth towards practice improvement, but also augmented the author’s 
academic and professional growth.  
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APPENDIX A. PERMISSION TO USE THE IOWA MODEL 
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APPENDIX B. IOWA MODEL  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Titler et al., 2015) 
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APPENDIX C. PAIN MANAGEMENT ALOGRITHM  
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APPENDIX D. MORPHINE MILLIGRAM EQUIVALENCE CONVERSION TABLE 
 
 
 
 
(USDHHS, 2016)
Commonly Prescribed Opioids  
 
Medication 50 MME Dose 
Equivalence 
Estimated Number of Dosages 90 MME Dose 
Equivalence 
Estimated Number of Dosages 
Hydrocodone  50 mg of 
hydrocodone  
10 tablets of 
hydrocodone/acetaminophen 5/325 
mg  
5 tablets of 
hydrocodone/acetaminophen 10/325 
mg 
90 mg of 
hydrocodone  
 
18  tablets of hydrocodone/acetaminophen 
5/325 mg  
9 tablets of hydrocodone/acetaminophen 
10/325 mg 
Oxycodone  33 mg of 
oxycodone 
~2 tablets of oxycodone sustained-
release 15 mg 
~6 tablets of oxycodone/acetaminophen 
5/325 mg 
~3 tablets of oxycodone/acetaminophen 
10/325 mg  
~6 tablets of oxycodone/ibuprofen 
5/400 mg 
60 mg of 
oxycodone  
4 tablets of oxycodone sustained-release 15 mg 
12 tablets of oxycodone/acetaminophen 5/325 
mg 
6 tablets of oxycodone/acetaminophen 10/325 
mg  
12 tablets of oxycodone/ibuprofen 5/400 mg 
Hydromorphone 12.5 mg of 
hydromorphone 
6 tablets of hydromorphone 2 mg 
3 tablets of hydromorphone 4 mg  
22 mg of 
hydromorphone   
 
11 tablets of hydromorphone 2 mg 
5.5 tablets of hydromorphone 4 mg  
Morphine  50 mg of 
Morphine  
~3 tablets of Morphine extended release 
15mg 
90 mg of 
morphine  
6 tablets of Morphine extended release 15mg 
Fentanyl 
Transdermal  
21 mcg/hr  (1) 12mcg/hr patch  
< 25 mcg/hr patch  
37.5 mcg/hr of 
Fentanyl 
transdermal  
(1) 12mcg/hr patch + (1) 25 mcg/hr patch  
 
Morphine Milligram Equivalence Conversion  
Calculating Morphine Milligram Equivalence (MME)  
 
•   Calculating Total Daily Doses that would be equivalent to 
MME/day  
o   (total number of desired MME/day)/(conversion factor)= 
Total daily dose equivalent to desired MME/day  
§   50 MME / conversion factor = total daily dose 
equivalent to 50 MME/day 
§   90 MME/ conversion factor = total daily dose equivalent 
to 90 MME/day 
•   Example: How many mg of hydromorphone is equal 
to 50 MME/day 
o   Desired MME/day 
o   Conversion factor = 4 
o   50/4=12.5  
o   12.5 mg of hydromorphone per day =50 
MME/day 
 
 
•   Calculating MME from patient daily intake  
o   (total number of tablets a day) x (medication dose) x 
(conversion factor) = Total MME/day that the patient is takin 
§   Example: Patient is prescribed hydrocodone/acetaminophen 
5/325 mg, 1-2 tablets every 4-6 hours 
o   Max number of tablets this patient can take a day is 2 
tablets every 4 hours 
o   24/4 = patient can take medication up to 6 times a day 
o   6x2 = 12 tablets  
o   Total number of tablets =12 
o   Medication dose = 5 mg of hydrocodone  
o   Conversion factor = 1  
o   12x5x1 = 60 
o   This patient is taking 60 MME / day with max dose  
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APPENDIX E. POST-EDUCATION QUESTIONNAIRE 
Please answer the following questions below on the presented education:  
1.   Did this session meet your educational needs?  
 
No Somewhat Yes 
£ £ £ 
 
2.   Did the information presented reinforce and/or improve your current skills? 
 
No Somewhat Yes 
£ £ £ 
 
3.   Did the information presented provide new ideas/information you expect to use?  
 
No Somewhat Yes 
£ £ £ 
 
Please rate the projected impact of this education activity on your competence, 
performance, and/or patient outcomes: 
4.   This activity increased my competence  
 
No Increase Moderate Increase  Great Increase 
£ £ £ 
 
5.   This activity will improve my performance 
 
No Increase Moderate Increase  Great Increase 
£ £ £ 
 
6. This activity will improve my patient outcomes  
 
No Increase Moderate Increase  Great Increase 
£ £ £ 
 
* Competence is defined as giving providers new abilities/strategies/knowledge with a strategy, or what a 
professional would do in practice if given the opportunity. 
** Performance is defined as helping physicians modify their practices.  
 
Answer the following questions regarding best practice for chronic opioid management:  
7.   What is your comfort level of caring for a chronic pain management patient?  
 
Very Poor Poor Acceptable Good Very Good 
£ £ £ £ £ 
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8.   Rate your understanding of who should be placed on a pain contract?  
 
Very Poor Poor Acceptable Good Very Good 
£ £ £ £ £ 
 
9.   Rate your understanding on the process to follow to place a patient on a pain 
management contract?  
 
Very Poor Poor Acceptable Good Very Good 
£ £ £ £ £ 
 
10.  Rate your understanding of how often the Prescription Drug Monitoring Program 
(PDMP) should be checked on chronic pain management patients? 
 
Very Poor Poor Acceptable Good Very Good 
£ £ £ £ £ 
 
11.  Rate your understanding on how often urine drug screens should be performed on chronic 
pain management patients?  
 
Very Poor Poor Acceptable Good Very Good 
£ £ £ £ £ 
 
12.  What is your understanding on how to care for patients that exceed 50 morphine 
milligram equivalence (MME) per day?  
 
Very Poor Poor Acceptable Good Very Good 
£ £ £ £ £ 
 
 
 
13.  Rate understanding on how to care for patients that exceed 90 morphine milligram 
equivalence (MME) per day?  
 
Very Poor Poor Acceptable Good Very Good 
£ £ £ £ £ 
 
14.   Rate your understanding of the recommendations provided by The 2016 Center for 
Disease Control and Prevention (CDC) guideline on chronic pain management?  
 
Very Poor Poor Acceptable Good Very Good 
£ £ £ £ £ 
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Write a brief description to answer the following questions: 
 
15.  What changes will you incorporate into your practice as a result of the knowledge 
acquired during this education?  
 
16.  How do you intend to take what you learned and improve the health of your patients?  
 
17.  What are the top three barriers to managing pain? 
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APPENDIX F. QUICK REFERENCE SHEET 
 
Quick Reference Sheet: 
Management of Patients Meeting the Upper Limit Morphine Milligram Equivalent 
Recommendations 
Opioids ≥ 50 MME/Day Opioids ≥ 90 MME 
(INTERVENTIONS for 50 MME/Day 
PLUS) 
1.   Reassess for evidence of benefits 
outweighing risks 
2.   Increased frequency of follow-ups  
•   Every 1-4 weeks  
3.  Consider offering naloxone and overdose 
prevention education to: 
•   The patient  
•   Members of the patient’s household  
o   Factors increasing overdose risk  
§   ≥50 MME/day  
§   History of overdose 
§   History of substance use disorder 
§   Concurrent benzodiazepine use  
•  Information on naloxone prescribing: 
http://prescribetoprevent.org 
4.   Referrals to: 
•   Pain specialist  
•   Behavior health specialist 
1.    Avoid prescribing doses ≥ 90 MME/day   
2.   Carefully justify and document decision to 
titrate dose ≥ 90 MME/day  
•   Discuss alternative approaches to pain 
management: 
o   Consider working with patients to 
taper opioids to a lower dose or 
discontinuation while maximizing 
nonpharmacological and non-
opioid pharmacologic treatments  
§   Slow taper  
o   10% of the original dose 
reduction weekly  
§   Rapid taper  
o   30-50% of the original dose 
reduction over 2-3 weeks  
 
 
Ø   Presenting signs of an opioid use disorder clinicians should provide:  
•   Treatment referral 
o   Methadone  
o   Buprenorphine  
§   Has higher rates of preventing relapse  
•   Behavioral therapy referral 
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APPENDIX G. IRB APPROVAL  
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APPENDIX H. EXECUTIVE SUMMARY  
Background and Significance  
Chronic pain is a growing issue in the United States, individuals affected by chronic pain 
are increasing each year. More than 50 million adults are affected by chronic pain each year. 
Americans affected by pain totals more than those with conditions such as: diabetes, heart 
disease, and cancer combined. Chronic pain affects many aspects of life for individuals living 
with it including but not limited to: neurological system, emotions, behavior, ability to perform 
daily tasks, ability to work, social responsibilities, and quality of life. The United States has an 
opioid consumption rate greater than any other nation. In 2015, prescription opioids account for 
nearly half of United States. opioid related deaths. More than 15,000 overdose deaths involving 
prescription opioids occurred in 2015, averaging about 46 people each day. Since 1999, 
prescription opioid related overdose deaths and opioid prescribing habits of providers 
have quadrupled. In 2012, 259 million opioid pain medication prescriptions were provided by 
health care providers, which is enough for every United States adult to have one bottle 
of opioids. Opioid pain medication is over-prescribed for individuals with all types 
of pain. Healthcare placing more emphasis on patient satisfaction scores is driving providers to 
achieve patient satisfaction. Chronic pain treatment in the United States has amounted to more 
than half a trillion dollars every year.  Healthcare costs of opioid abusers were eight times higher 
than non-opioid abusers. Chronic non-cancer pain has been found to be the leading cause of 
long-term disability. Rates of prescription opioids are concerning, and action needs to be taken.  
Project Summary  
The purpose of the project quality improvement project is to provide clinicians with tools 
and processes that will reduce problematic prescribing and subsequently reducing current and 
 92 
potential misuse, abuse, and overdose. Use of evidence-based guidelines in practice offer 
possible solutions to problematic prescribing, change prescribing habits, improve provider 
knowledge, optimize care, and improve patient safety. The Population of the project will include: 
all patients 18 years and older on chronic opioid therapy. The setting of the project is Coal 
County Community Health Center which is a healthcare facility with four locations in rural 
North Dakota. The project started with an education session organized for all clinicians and 
patient care staff to provide education regarding the CDC guideline elements, current 
recommendations, and accepted best practices. Education highlighted the importance of using 
the prescription drug monitoring program (PDMP), urine drug screening (UDS), pain contracts, 
and calculating daily morphine milligram equivalence (MME). A laminated copy of an algorithm 
based upon the CDC guideline and pre-calculated MME doses for popular opioids was be 
provided to all clinicians. A post-education session questionnaire was given to all providers. The 
questionnaire focused on current understanding of information provided during the education 
session. Five main objects were carried out. Patients with existing pain contracts were identified 
and a flag reading “CS Consent” was developed in collaboration with informational technology 
services (ITS). The flag “CS Consent” was added onto the face sheet new patient alerts on the 
patients EHR. Patients prescribed opioids ≥ 3 months will be identified for pain contract 
eligibility. A list of identified patients will be provided to clinicians and will be flagged in the 
EHR as “Eligible for CS Consent.” Patients receiving opioids for ≥ 3 months and prescribed the 
upper limits of morphine milligram equivalence (MME), ≥ 60 and ≥ 90 MME per day, were 
identified through a chart audit. A list of these patients was provided to clinicians and 
encouraged to follow current recommended interventions for patients. At the end of the project 
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the quality coordinator was designated to take responsibility to ensure providers compliance with 
appropriate use of PDMP, UDS, and MME.  
Results 
Post-Education Questionnaire Results 
A post-education questionnaire was provided to 10 clinicians who attended the education 
session on August 30, 2017. After the education session was completed, an open discussion was 
held between the providers and remaining 37 clinical staff in attendance. Nine of the 10 
providers returned the questionnaire with responses. The remaining providers did receive but did 
not return the questionnaire. Following are the questions asked and the provider’s responses 
taken from the questionnaires. 
The first three questions focused on the education presented during the education session. 
Responses to questions one through three were based on a three-part response including no, 
somewhat, and yes. The first question on the questionnaire asked if the educational session met 
the provider’s educational needs on chronic pain management. All nine providers answered yes, 
indicating that their educational needs on chronic pain management were met. Question two 
asked if the information presented reinforced and/or improved their current skills. All nine 
providers answered yes. The third question on the survey asked providers if the educational 
session provided new ideas and information that they expect to use in practice. Eight of the nine 
providers answered yes and one provider answered no. 
Questions four through six focused on the projected impact the education had on their 
competence, performance, and/or patient outcomes. Responses to questions four through six 
were based on a three-part response including no increase, moderate increase, and great increase. 
Question four asked if the education session increased their competence on chronic pain 
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management. Three providers responded great increase and six providers responded moderate 
increase. The fifth question on the questionnaire asked if the education session will improve the 
provider’s performance. Two providers responded great increase and seven providers responded 
moderate increase. Question six asked if the education session will improve patient outcomes. 
Three providers responded great increase and six responded moderate increase. 
Questions seven through fourteen were in regard to the best practices for chronic opioid 
management. Responses to questions seven through 14 were based on a five-part response 
including very poor, poor, acceptable, good, and very good. Question seven asked the provider’s 
comfort level of caring for a chronic pain management patient. Two providers responded very 
good, four responded good, two responded acceptable, and one responded poor. The eighth 
question on the questionnaire had providers rate their understanding of who should be placed on 
a pain contract. Five providers responded very good, three responded good, and one responded 
acceptable. Question nine asked providers to rate their understanding of the process to follow to 
place a patient on a pain management contract. Four providers responded very good, four 
responded good, and one responded acceptable. The tenth question on the survey had providers 
rate their understanding of how often the PDMP should be checked on chronic pain management 
patients. Five providers responded very good and four responded good. Question eleven asked 
providers to rate their understanding on how often urine drug screens should be performed on 
chronic pain management patients. Five providers responded very good, three responded good, 
and one responded acceptable. The twelfth and thirteenth questions on the questionnaire asked 
providers their understanding on how to care for patients that exceed 50 MME per day and 90 
MME per day, respectively. For both questions, three providers responded very good, three 
responded good, two responded acceptable, and one responded poor. Question fourteen asked 
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providers to rate their understanding of the recommendations provided by the 2016 CDC 
guideline on chronic pain management. Three providers responded very good, four responded 
good, and two responded acceptable. 
The final three questions on the questionnaire were open ended. One question focused on 
the education provided and areas of concern when treating chronic pain management. Providers 
still had concerns about:  
•   contributing to opioid dependence  
•   addressing high MME dosages with patients  
•   the difficulty caring for non-compliant patients 
•   lack of resources in the immediate area such as pain specialist and mental health care 
•   lack of experience caring for pain management patients 
•   trying to effectively offer and treat with alternative treatment options when appropriate 
•   referring patients back to the primary care provider 
•   the time it takes to care for patients with chronic pain and not having enough time to 
provide the care needed 
•   pain is subjective leaving it difficult to know when to treat and not treat 
•   patients misusing pain medication often become manipulative 
Question sixteen providers what issues should the system address to help you improve 
management of chronic pain. Provider responses included:  
•   provide an easy spot to see the pain contract that is in place 
•   implement reminders that patients are on contracts 
•   identify on the EHR if the patient has been dismissed from their contract 
•   system notification of when pain contract patients are due for a UDS 
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•   wishes the current EHR system could calculate MME 
•   reminders for checking records, dosages, and drug screens 
•   simplified pain management charting to make charting easier  
Question seventeen asked what are the top three barriers to managing chronic pain. 
Providers responses included:  
•   trouble with subjective symptoms leading to a treatment plan 
•   difficulty trusting patients 
•   difficulty confronting patients 
•   stigma associated with opioid use 
•   patient compliance 
•   the psychosocial component 
•   the lack of consistency across different providers 
•   lack of resources in rural health, patient expectations 
•   educating patients, pain is subjective 
•   patients lie/ manipulative patients 
•   patients sell and traffic their medications 
•   lack of pain management options 
•   cost of urine drug testing 
•   the PDMP does not include all 50 states yet 
communication barriers, and pain assessment 
Initial Chart Review Results  
The author performed an initial chart review in August 2017 prior to the education 
session. The initial chart review included 364 charts of patients who were being prescribed 
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opioids. Data collection identified if the patients were prescribed opioids for ≥ 3 months and if 
they were on a pain contract. Forty-two patients were found to have a pain contract and 17 more 
patients were identified as being eligible for a pain contract. The 42 charts reviewed of patients 
previously identified on a pain contract revealed zero patients had a PDMP report scanned into 
the EHR. The chart identified nine of the 42 patients or 21% on a pain contract had a UDS 
performed in the past year. Morphine milligram equivalence was evaluated for all patients on a 
pain contract. Seven of the 42 pain-contract patients or 16.7% were being prescribed dosages ≥ 
50 MME per day and nine of 42 or 21% were being prescribed dosages ≥ 90 MME per day. Data 
analysis was also performed on patients who were eligible for pain contracts. Three of the 17 or 
17.6% of patients were being prescribed ≥ 50 MME per day and five of 17 or 29% were being 
prescribed ≥ 90 MME per day.  
Final Chart Review Results  
The final chart review was moved from six down to four months with approval from the 
project committee. This change addressed time constraints of the project due to delays in IRB 
approval and scheduling with the clinics to initiate the project. The final chart review was 
completed the first week of January 2018. The same data was reviewed and analyzed as the 
initial chart review.  
 The initial 42 patients identified on pain contracts were evaluated and three were placed 
on the facilities restricted list, three had their pain contract discontinued, and two were no longer 
being prescribed opioids because they moved out of state. Thirty-four of the original 42 
remained on a pain contract. Thirty-four patient’s charts were flagged with “CS consent” on the 
face sheet under patient alert notes. Evaluation of patients eligible for a pain contact identified 
two patients had documentation justifying a reason why the patients were not placed on a pain 
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contract. Both patients were prescribed opioids for ≥ 3 months but took one or two opioid pills 
per week. Opioid therapy was discontinued for two of the eligible patients.  
Based on this new data, the number of eligible patients who should be placed on a pain 
contract decreased to 13. Eleven out of 13 or 85% of the eligible patients were placed on a pain 
contract. Eleven out of 11 or 100% of eligible patients placed on a pain contract had been 
flagged with “CS Consent and initiation date” in the EHR under patient alert notes.  
At the end of the project 45 patients had a pain contract, combining the 34 patients who 
initially were on a pain contract and the 11 eligible patients who were placed on a pain contract. 
Analyzing documented PDMP use data indicated 7 of the 11 or 64% of patients that were 
eligible and enrolled on a pain contract had a PDMP checked within the last three months. 
Eleven out of 34 or 32% of patients with an existing pain contracts had PDMP review 
documentation. The data for urine drug screens were collected through the chart review and 
seven out of 11 or 64% of patients who were eligible and enrolled on a pain contract had a UDSs 
performed at initiation of the pain contract. Eight out of 34 or 24% of patients previously on a 
pain contract had a UDS performed since initiation of the project.  
 Evaluation of MME interventions showed a total of three patients who were eligible for a 
pain contact and four who were previously on a pain contract were being prescribed ≥ 50 MME 
per day. One out of three or 33% of eligible and enrolled patients and three out of four or 75% of 
patients previously on a pain contract had documented appropriate recommended interventions. 
Upon evaluation of patients prescribed ≥ 90 MME per day five patients eligible for a pain 
contract and nine patients previously on a pain contract were identified. Morphine Milligram 
Equivalence data analysis revealed two of the five or 40% of patients who were eligible and 
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enrolled in a pain contract and five out of nine or 56% of patients previously on a pain contract 
had appropriate interventions provided by providers. 
Discussion 
The practice improvement project identified opportunity: potential improvement in both 
prescribing practices and chronic pain management of opioids. Findings showed providers 
increased their knowledge and comfort in using evidence-based practice guidelines. Based on the 
post-education questionnaire, providers identified lack of comfort in calculating safe MME daily 
doses and caring for patients with at-risk doses. Continuing education focused on MME dose 
calculation and patient care for high risk doses could potentially overcome this barrier. 
Discussion with individual providers revealed significant interest and need for improved 
opioid prescribing and monitoring strategies concerning chronic pain management patients. The 
chart review revealed that four of the providers followed all recommendations and accepted best 
practices fully. The remaining providers followed only certain elements while others did not 
follow any elements of the recommendations and accepted best practices. After expressing 
concerns about prescribing, some providers showed improved knowledge and comfort in use of 
guidelines but continued their current practice. Further education and intervention may help 
overcome this hurdle. 
Results showed that many providers improved evidence-based monitoring strategies — 
strategies designed to improve provider prescribing practices and reduce the risk of long term 
opioid use. Although improved, further intervention could build on current monitoring strategies 
leading to increased adherence by providers. Interventions may include further education or EHR 
based reminders for checking PDMP’s and collecting UDS’s. 
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Identifying patients eligible for enrollment in a pain contract was an important aspect of 
the project. The project identified patients eligible for a pain contract, based on a history of being 
prescribed opioids ≥ 3 months. Providers demonstrated excellence in enrolling eligible patients 
in pain contracts. Results can be interpreted in different ways but the results clearly show that 
providers understand the importance of recognizing patients using opioid long term. Providers 
may be hesitant to acknowledge that monitoring strategies can promote positive outcomes and 
reduce risks associated with long term opioid use. Further research and education could 
demonstrate and promote monitoring strategies among providers to improve adherence 
 EHR chart flagging was a need identified early in project development by the 
implementing facility. A universal flagging system within the EHR allowed providers to easily 
identify pain management patients. Providers said the flag became especially helpful when 
seeing another provider’s patient enrolled in a pain contract.  
Overall the project showed improvement in all interventions carried out. Further 
interventions, building on the project foundation, could further improve outcomes. Allowing 
providers more time to carry out interventions may be a key tool in continuation of the project. 
Further research is needed for determining if these combined interventions produce improved 
patient outcomes. 
Recommendations 
  Strategies for project maintenance was built into the project objectives. The data analysis 
showed improvement in most areas of monitoring chronic pain management care. The two areas 
failing to show substantial improvement were providers following appropriate interventions for 
patients being prescribed ≥ 50 MME per day and annual urine drug screens. Recommendations 
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for the facility include continued use of the 2016 CDC chronic pain management guideline 
recommendations and accepted best practices.  
The author would recommend that the facility implement a nurse driven protocol for new 
chronic pain management patients taking opioids. Nurse driven protocols have shown to help 
improve standardization, communication and outcomes while reducing patient harm (Committee 
on Professional Liability & Committee on Patient Safety and Quality Improvement, 2015). The 
protocol would provide strategies for the health care team to easily identify the chronic pain 
management population and remember guideline recommendations and best practices. This 
protocol would encourage nursing staff once a pain contract was initiated to flag “CS Consent” 
under patient alert notes, enter an annual health maintenance reminder and collect and order a 
UDS if appropriate, check the PDMP, and calculating the MME daily dosage.  
 Recommendations include strategies for improved collection and review of annual urine 
drug screens and continued evaluation of daily MME dosing. Initiating an annual health 
maintenance reminder for urine drug screens on all patients currently identified on a chronic pain 
management contract would help the provider (Alvandi, 2015). The reminder would eliminate 
the time it takes to provider to review charts in the last year in an attempt to figure out when a 
patient will need their annual UDS. Recommendations for a maintenance reminder for an annual 
review of the patients MME dosing would be appropriate. It may also be helpful if these two 
reminders could be grouped into one.  
Recommendations for the facility include continued work towards implementing 
evidence-based strategies and recommendations set forth by the improvement project. For further 
growth, the author recommends that the quality coordinator works closely with the director of 
patient care and innovation to build on the foundation the project has made. It would be 
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important to analyzed data pulled biannually by the quality coordinator and the progress shared 
with providers. Data analysis will allow the facility to understand were adjustments need to be 
made and where to focus further efforts. Through this process the foundation of the project 
would be strengthen and built upon for continued improvement in chronic pain management.  
 
 
